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Abstract 
Although the incidence is quite low, epithelial ovarian cancer (EOC) is the most 
lethal gynaecologic malignancy. The unfavourable prognosis and the high mortality 
rate associated with EOC are mainly owed to late diagnosis, frequent relapse and 
development of chemoresistance. Indeed, most of the patients who achieve a 
complete response to first-line platinum-based treatment eventually relapse often 
developing platinum-resistant disease. Due to their master regulatory role, miRNAs 
are considered powerful tools to obtain representative molecular portraits of 
specific tumour characteristics and behaviours. My laboratory performed microRNA 
expression profiles on advanced stage EOC patients and a cluster of miRNAs, 
including miR-506, located on ChrXq27.3 was identified as down-regulated in EOC 
early relapsing patients. Since I observed that expression of miR-506 was associated 
with EOC patients’ sensitivity to platinum treatment, the overall aim of this thesis 
was to better characterize the role of this miRNA in regulating response to 
chemotherapy. Among the miR-506 predicted targets, I identified several genes 
involved in DNA damage repair (DDR) pathway, like RAD51, RAD17, CHEK1 and WEE1 
and I concentrated on genes not previously studied in EOC. I validated RAD17 as a 
direct target of miR-506 and identified the miR-506-RAD17 axis as relevant in 
chemosensitising EOC cells to different treatments. I demonstrated that miR-506 
expression, by targeting RAD17, was able to mediate sensitisation to platinum 
treatment and accordingly RAD17 silencing exerted the same effect. MiR-506 
expression in EOC cells led to a reduced ability to properly sense DNA damage 
following platinum treatment causing mitotic defects, micronuclei formation, and 
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impairing the signalling cascade responsible for G2/M checkpoint activation upon 
DNA damage insults. This behaviour, recapitulating a BRCAness phenotype, would 
allow propagation of cells with unrepaired DNA damage with the subsequent 
sensitisation to DNA damaging drugs. Furthermore, miR-506 expression, by 
regulating RAD17, impairs ATM signalling pathway, sensitising EOC cells to PARP 
inhibitor olaparib. Acting in the same way, miR-506 expression was synthetic lethal 
with Chk1 and Wee1 checkpoint kinases inhibitors in agreement with recent data 
reporting RAD17 depletion to be synthetically lethal with these small molecules. 
Accordingly, RAD17 down-modulation phenocopied the effect of miR-506 
expression. Also combination treatments of Checkpoint kinases inhibitors with 
platinum resulted to be synergistic. Together the findings presented in this thesis 
support miR-506 as a key node in regulating DDR pathway in response to drug 
treatments and provide the rationale for its use to select EOC patients with 
BRCAness phenotype for efficient personalized therapeutic treatments. 
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1.1 Epithelial ovarian cancer 
1.1.1 Clinical aspects 
Epithelial ovarian cancer (EOC) is the leading cause of death among gynaecological 
cancers in the developed world1 and it is characterised by high pathological and 
molecular heterogeneity and with a high fatality rate2. The absence of early and 
specific symptoms and the lack of screening strategies3 contribute to late diagnosis. 
As a result, most cases of EOC do not come to clinical attention with a confined 
mass in the ovary, but more often patients present with advanced stage III/IV 
disease. According to International Federation of Obstetrics and Gynaecology 
(FIGO) criteria, the advanced stage is characterised by a widespread intraperitoneal 
disease with the involvement of different pelvic structures other than ovary and 
intra-abdominal ascites. The standard of care for EOC is cytoreductive surgery, 
followed by six to eight cycles of a combination of platinum- and taxane-based 
chemotherapy as first-line treatment for advanced EOC1. Although up to 80% of 
patients can be placed into remission after surgery and chemotherapy, the majority 
of them will relapse with a median progression-free survival of 18 months and a 5-
years survivorship being below 40% 2, 3. The length of the disease-free period 
categorises patients as: refractory or resistant if relapse occurs during or within 6 
months of the end of chemotherapy, partially sensitive when relapsing after 6 and 
before 12 months, sensitive when relapsing after 12 months from the end of 
treatment4. Disease relapse following front-line treatment is frequently associated 
with the development of chemoresistance that, together with a late detection of 
the disease represents the main problem to overcome in the management of EOC. 
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Unfortunately, no validated screening tests are available for the general population 
and the identification of new biomarkers for early diagnosis or disease progression, 
prognosis and response to therapy are of great interest to improve the 
management of this aggressive malignancy. 
1.1.2 Histological subtypes and Origins of ovarian cancer 
- Histological subtypes 
The three main types of ovarian cancer classified by the World Health Organization 
(WHO) include epithelial ovarian cancers (EOC), whose origin is still an area of active 
investigations (commented below), malignant germ cell tumours, which develop 
from the cells that produce the oocyte, and sex cord stromal tumours, which 
develop from connective tissue cells that hold the ovary5. EOC is the most common 
type and represents 90% of malignant ovarian tumours6. Histological subtypes of 
EOC include: high grade serous, low grade serous, endometrioid, clear cell and 
mucinous tumours7 as represented in Figure 1.  
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Figure 1: Defining EOC origins  
Site of origin of EOC is still debated. Recent evidences suggest that HGSOC originates from 
the fallopian tubes, and then metastasize to the ovary. Image from Ovarian Cancers. 
Evolving Paradigms in Research and Care (2016). 
 
Morphological and molecular genetic studies have elucidated our understanding of 
ovarian carcinogenesis.  Almost 10 years ago, a new classification was proposed 
that, according to cell type and molecular features and on the basis of a dualistic 
model of carcinogenesis, divides the histological types of EOC into two categories 
designated as type I and type II tumours8 (Figure 2). Type I tumours comprise Low 
Grade Serous Carcinomas (LGSOCs), low grade endometroid tumours, clear cells 
and mucinous carcinomas. Overall these tumours account for only 10% of deaths 
from EOC. They are generally indolent with a good prognosis when masses are 
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confined to one ovary (stage I) but with a poor outcome when diagnosed at 
advanced stage. Type I tumours are associated with frequent somatic mutations in 
KRAS, BRAF, CTNNB1, PTEN, PIK3CA, MAP, ERK and ARID1A, with rare mutational 
events occurring in TP539. In contrast, Type II tumours present at more advanced 
stages and constitute approximately 75% of ovarian tumours, and are responsible 
for 90% of EOC deaths. Type II tumours are largely composed of High Grade Serous 
Carcinomas (HGSOCs), carcinosarcoma and undifferentiated carcinoma. Extensive 
gene expression profiling studies, mostly performed in HGSOC, substantially 
improved the knowledge of EOC biology and were also expected to significantly 
improve the management of EOC patients. Novel molecular subtypes of EOC based 
on gene expression profile were firstly identified by the Australian Ovarian Cancer 
Study10, then the Cancer Genome Atlas (TCGA) validated the study identifying four 
molecular subtypes whose prognostic significance has been recently validated11, 12. 
However their clinical utility is still a challenge. HGSOCs are genetically unstable and 
almost all harbour a mutation in the TP53 13. These studies revealed the complexity 
and the molecular heterogeneity of HGSOC and indeed, the performance of these 
survival signatures differ among independent cohorts, indicating that the use of 
these signatures for EOC patient management is still a challenge. Moreover 
different abnormalities in homologous recombination repair (HRR) (such as 
mutations or epigenetic alterations in BRCA1 (Breast Cancer 1) and BRCA2 (Breast 
Cancer 2), and defects in Rb protein, Cyclin E1, FOXM1 and NOTCH3 signalling 
pathways often occur in type II tumours9, 12 (Figure 2).  
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Figure 2: The revised dualistic model in the pathogenesis of EOC 
Type I and Type II tumour classification with areas in individual histotypes reflecting their 
relative prevalence. The inner circle indicates the likely cell of origin of the different type I 
and type II tumours indicated in the external circle. The square boxes summarized the 
molecular tumour alterations of the different subtypes. HR: Homologous Recombination; 
DDR: DNA Damage Response. Image from Kurman and Shih11. 
 
- Origins of ovarian cancer 
The traditional dogma of ovarian carcinogenesis was that EOC arises from ovarian 
surface epithelium (OSE) which gives rise to cortical inclusion cysts (CICs) that 
undergo malignant transformation14. The fact that EOCs are composed of cells that 
do not resemble cells in the ovary made OSE origin theory hard to be sustained. It is 
now well sustained by several lines of evidence the hypothesis that many HGSOCs 
arise from high grade serous tubal intraepithelial carcinomas (STICs) that shed from 
the fallopian tube into the ovary15. This paradigm shift has profound implications in 
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the management of this disease and has begun to affect treatment strategies. 
However definition of site of origin is still a matter of debate16.   
The dualistic model dividing EOC in type I and type II tumours present limitations 
indeed dramatic differences between the two groups  are now emerging describing 
completely different groups of diseases and demonstrating that EOC is not a single 
disease but a set of different types of cancer with very different pathological and 
clinical features17-19. Thanks to the huge number of molecular and histopathological 
studies that have provided new insights into the origin and molecular pathogenesis 
of this disease, the standard model has been further revised and expanded11. It is of 
course important when studying ovarian cancer to distinguish by type taking into 
account also the huge quantity of molecular new data that are now available in 
order to improve diagnosis and treatment of this aggressive disease. 
 
1.1.3 Treatments 
The treatment of ovarian cancer is characterised by a combination of aggressive 
cytoreductive surgery followed by platinum based chemotherapy with new targeted 
therapeutic options now available for selected patients and driven by molecular 
characterisation of EOC (see section 1.1.5) The main purpose of the surgery is to 
remove the bulk of the tumour and establish the histopathological diagnosis (FIGO 
stage). As a result, the accurate resection of the entire visible tumour is of primary 
importance since residual disease remains a strong prognostic factors and optimal 
cytoreduction is associated with longer survival20. For advanced stage tumours, 
platinum-based chemotherapy remains the standard of care. 
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1.1.4 Platinum agents: mode of action and resistance in EOC 
- Mode of action 
The mechanism of action of platinum agents relies on their ability to bind to DNA to 
form bulky adducts which require effective repair to prevent apoptosis. Intra-strand 
DNA cross-links are the most common cytotoxic lesions caused by platinum 
treatments21, 22. These platinum-induced lesions cause distortions of the DNA 
structure that are recognized by multiple DNA Damage Repair (DDR) pathways23. In 
particular NER (nucleotide excision repair) and MMR (mismatch repair) repair 
pathways are primarily activated for the resolution of platinum lesions24, 25, then 
also HRR (homologous recombination repair) and ICL (interstrand crosslinks) repair 
are activated when lesions increase (overview of repair mechanisms in section 1.2). 
The cell cycle also takes a role in repair processes and if damage is limited, cells 
arrest in the S and G2 phase of the cell cycle to repair their damage, if the extent of 
lesions increases, cells are no longer able to repair the damage and are committed 
to death26. 
- Platinum resistance 
Drug resistance is a major problem associated with the use of platinum agents. 
While the intrinsic model of resistance is based on the pre-existence of a small 
proportion of chemotherapy-resistant tumour cells that after treatment repopulate 
the tumour and recurrence is observed (refractory disease), acquired resistance is 
based on an initial platinum sensitivity of tumour cells that, following multiple 
cycles of platinum-based chemotherapy, may acquire resistance. In both cases, 
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unravelling the mechanisms of resistance to platinum agents remains a critical goal 
for EOC therapy. 
Platinum resistance is a multifactorial event driven by different molecular 
mechanisms including genetic or epigenetic alterations, inaccessibility of drugs in 
cancer cells, increased ability to tolerate or repair DNA lesions27. Dysregulation of 
cell ability to repair DNA damage is one of the prevalent factors that lead to 
platinum resistance. Platinum-resistant cells acquire the ability to tolerate and 
repair platinum induced adducts through different mechanisms. Dysfunctions in 
genes involved in NER pathway such as overexpression of ERCC1 (Excision Repair 
Cross-Complementation Group 1), or ERCC2 (Excision Repair Cross-
Complementation Group 2), proteins participating in NER, have been correlated 
with poor survival in advanced EOC and were found to be markers of resistance to 
platinum-based drugs28, 29. Components of MMR, such as MSH2 (MutS Homolog 2) 
and MLH1 (MutL Homolog 1), are often mutated or low expressed in platinum-
resistant tumours, including EOC, where MLH1 promoter methylation predicted 
poor survival in relapsing patients30-33. Platinum induced adducts such as interstrand 
crosslinks, require also homologous recombination repair (HRR), an accurate type of 
repair with exchange of homologous DNA sequences in which BRCA1 and BRCA2 are 
major players. These genes are often mutated in HGSOC. Interestingly EOC patients 
carrying BRCA1/2 mutations are sensitive to platinum treatment and have a better 
overall prognosis34, 35. However, in platinum-resistant tumours compensatory 
mutations that restore BRCA function and re-establish a correct HRR have been 
shown to favour acquired chemoresistance36-38. In addition to DNA repair 
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dysfunction, the internalization and degradation of copper transporter 1 and 2 
(Crt1, Crt2), which mediate platinum uptake, also contributes to resistance in 
ovarian cancer due to reduced availability of the drug within the cell39, 40. Two other 
components of the copper family, ATP7A and ATP7B, mediate efflux of drugs and 
were reported to be overexpressed in platinum-resistant EOC cells41, 42. Interestingly 
Patch and colleagues performed a whole genome analysis on tumour samples from 
patients with primary refractory, resistant, sensitive and matched acquired resistant 
disease and observed heterogeneity of the genome under the selective pressure of 
chemotherapy. Among major findings, they observed changes in promoter 
methylation or reversion of mutational status of BRCA genes and up-regulation of 
multidrug-resistant protein 1 (MDR1) transporters, that mediate efflux of drugs43, 
mediated by a novel fusion gene not previously reported in which the promoter of 
SLC25A40 was juxtaposed with ABCB1 which encodes for MDR1. These findings 
further support the acquired platinum resistance model and the idea of cells 
adaptation to survive. 
1.1.5 Molecular driven therapeutics for EOC 
Advances in routine genomic studies (next-generation sequencing, expression 
profiles) are now providing new insight into individual genetic abnormalities for a 
more personalized medicine. Beyond platinum-based therapy, ovarian tumours can 
be now treated with targeted therapies as an alternative strategy for selected 
patients. One example is the case of tumours with BRCA abnormalities. As 
previously said, patients who harbour mutations in BRCA1 and BRCA2 show 
deficiencies in HRR, one of the main mechanisms for the repair of DNA double 
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strand break damage. These tumours appear sensitive to poly (ADP-ribose) 
polymerase (PARP) inhibitors and olaparib, rucaparib and niraparib are now 
therapeutic options for these patients44, 45 46 47. Moreover tumours presenting wild 
type BRCA1/2 but bearing HRR defects and therefore sharing molecular features of 
BRCA mutated tumours, may also respond to similar therapeutic approaches44 46 47. 
This concept, firstly introduced by Ashworth and collaborators more than 10 years 
ago and named BRCAness48, 49, is generally associated with mutations of other genes 
of the same signalling pathway and may thus have important implications for the 
clinical management of these cancers48, 50, 51.  
Another example of approved targeted therapy for ovarian cancer is Bevacizumab, 
a humanized monoclonal antibody that binds to vascular endothelial growth factor 
A (VEGF-A), a protein that promotes the formation of new blood vessels 
(angiogenesis) for nutrients delivery to tumour cells. Bevacizumab, blocking 
angiogenesis, blocks the growth by tumour cell starvation. Bevacizumab is also able 
to initiate vessel normalization leading to vessel permeability for an improved 
tumour drug uptake and increase of partial oxygen thus reducing hypoxia52, 53. 
Bevacizumab was recently approved as first line treatment and maintenance 
chemotherapy. This evidence suggests the importance of better defining the 
molecular landscape of the different subtypes of ovarian carcinoma in order to 
stratify patients for tailored therapy.  
1.2 DNA Damage Repair Mechanisms 
DNA is the repository of genetic information and maintaining its integrity and 
stability is essential to life. Many type of lesions can affect DNA including 
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endogenous metabolic products such as reactive oxygen species (ROS), external 
chemical agents such as cytotoxic chemotherapeutic agents (platinum-agents) or 
electromagnetic radiations (ionizing radiation or UV lights). When lesions happen in 
one strand of DNA, single strand breaks (SSBs) occur; when both strands of DNA are 
involved we observe double strand breaks (DSBs). DSBs are the most dangerous 
among lesions54 which if not correctly repaired can lead to genomic instability55. In 
order to avoid such genomic instability cells can use, the so called DDR (DNA 
Damage Response), to sense DNA damage and mediate appropriate cellular 
response and repair.  
1.2.1 DNA damage sensors 
DNA damage sensors detect the DNA lesions for initiating DDR. The Mre11–Rad50–
Nbs1 (MRN) complex is a sensor of the DNA damage responsible for processing DNA 
ends and recruits other molecules of the DDR at damaged sites26, 56. The DNA lesion 
recognition leads to activation of Ataxia Telangiectasia Mutated (ATM) or Ataxia 
Telangiectasia and Rad3 Related (ATR) kinases, in particular, ATM is activated by 
DSBs recognition while ATR by stalled replication forks57, 58. Then a signal cascade is 
propagated with the recruitment of the other members that participate in this 
complex pathway for DNA damage repair and the activation of checkpoints for cell 
cycle regulation (overview in section 1.3). 
1.2.2 Mechanisms of DNA repair 
Each type of damage acts in a specific way determining a different type of damage 
detection and repair mechanism activation as schematically shown in Figure 3. DSBs 
lesions are preferentially repaired by two pathways, the homologous recombination 
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repair (HRR) and non-homologous end joining (NHEJ). HRR is an error free repair 
pathway relying on the presence of a sister chromatid as template to for accurate 
DNA repair and is the most used mechanism by cells for repairing DSBs and 
restarting stalled replication forks. The error-prone NHEJ mediates the ligation of 
the two ends of DNA DSBs without the need of a homologous template59. SSBs are 
repaired by differ mechanisms in which the intact complementary strand can be 
used as a template to repair the damaged strand. In particular base excision repair 
(BER) resolves damage to a single base mainly caused by oxidation or alkylation; the 
nucleotide excision repair (NER) is activated for the repair of helix-distorting lesions 
(bulky adducts such as pyrimidine dimers) and mismatch repair (MMR) is activated 
to corrects errors of DNA replication and recombination56. 
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Figure 3: DNA damage sources and mechanisms of repair  
Schematic overview of the different environmental factors and endogenous cellular 
processes responsible for DNA damage. Cells have developed different repair mechanisms 
in order to fix these damages such as DNA base excision repair (BER), single strand break 
repair (SSBR), nucleotide excision repair (NER), mismatch repair (MMR), homologous 
recombination (HR), and Non-homologous End Joining (NHEJ), activated by different types 
of damage insults. Checkpoint signalling is also activated in order to arrest cell cycle 
progression to facilitate DNA repair.  
Image from http://www.genetex.com/Web/News/NewsList.aspx?id=322 
 
1.3 Cell cycle and checkpoints activation in cancer 
Among the events activated during DDR there is the delay or block of the cell cycle 
progression to give time for the cell to repair any DNA lesions prior to replication or 
mitosis. The cell cycle is an ordered series of events that regulate cell growth and 
proliferation leading to the formation of two daughter cells that receive a correctly 
duplicated copy of genome and organelles from the parental cell. Control 
mechanisms act during the cell cycle to ensure a correct duplication preventing cells 
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to divide under unfavourable conditions (for instance, when their DNA is damaged) 
and give them time to repair damage60. The G1 checkpoint (controlling the G1 to S 
transition), is the first restriction point after which cells become committed to 
entering the cell cycle61. Once the cell passes the G1 phase and enters S phase (DNA 
duplication phase), it becomes irreversibly committed to division. Cells have an 
additional checkpoint before M (mitosis) phase, called the G2 checkpoint. At this 
stage, the cell will check DNA integrity and DNA replication. If errors or damages are 
detected, the cell will pause at the G2 checkpoint to allow for repairs62, 63. Among 
Checkpoint kinases involved in DDR, ATM and ATR act as sensor proteins of the 
damage and consecutively phosphorylate mediator proteins, such as Chk1 
(checkpoint kinase 1) and Chk2 (checkpoint kinase 2), that transduce signal. Chk1 
and Chk2 block cell cycle progression through phosphorylation and inhibition of 
CDC25 phosphatases required for cyclin dependent kinase (CDK) activation. This 
results in sustained inhibitory phosphorylation of CDK1 and CDK2 leading to cell 
cycle arrest. Wee1 protein is also involved in the control of cell cycle progression 
being responsible of inhibitory phosphorylation of CDK1 and CDK264. In Figure 4 are 
summarized the molecular events of cell cycle checkpoints activation upon damage. 
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Figure 4: DNA damage-induced cell cycle checkpoints 
DNA double-strand breaks (DSBs) and single strand breaks (SSBs) induce activation of 
ataxia-telangiectasia mutated (ATM) and ataxia-telangiectasia and Rad3-related (ATR) 
kinases which phosphorylates and activates the checkpoint effector kinases CHK2 and CHK1 
respectively. CHK2 phosphorylates cell division cycle 25A (CDC25A), which can prevent 
replication of damaged DNA by activating p53 and p21, resulting in G1/S checkpoint arrest 
due to inhibition of CDK2-cyclin complex. CHK1 phosphorylates cell division cycle 25C 
(CDC25C) which dephosphorylates CDK1 resulting in CDK1-Cyclin /B complex inhibition thus 
inducing G2/M checkpoint arrest to allow DNA repair. In addition, G1/S and G2/M 
checkpoint are maintained blocked by WEE1 kinase that inhibit dephosphorylation of 
CDK1/2. Image from Lin AB et al64. 
 
p53 is a cell cycle G1 checkpoint regulator which, when impaired, forces cells to rely 
on other checkpoints for cell cycle regulation. Interestingly HGSOC are characterised 
by near universal aberration in the tumour suppressor TP53 13. Focusing on p53 
deficiency as the target selection criteria, it becomes evident that targeting the G2 
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checkpoint could represents a valuable strategy to kill cancer cells sparing normal 
cells protected by a p53-dependent response65 (Figure 5). As a result, maximising 
the DNA damage during G1 and prevent repair in G2 should be the goal for the use 
of DDR targeted therapy. Indeed G2/M checkpoint abrogation, can ultimately lead 
to mitotic catastrophe and cell death or senescence. 
 
 
 
Figure 5: Sensitizing cancer cells to DNA-damaging agents with checkpoint inhibitors 
Cancer cells deficient in p53 lack the G1 checkpoint and may depend more on the G2/M 
checkpoint to block cell cycle and repair damage. Checkpoint inhibitors in combination with 
DNA damaging therapy leads to the G2/M checkpoint abrogation that culminate in mitotic 
catastrophe and cell death. Notably, healthy cells are protected by p53-dependent 
response. Image from Benada J et al65. 
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1.3.1 RAD17 
RAD17 is a DNA damage checkpoint gene firstly identified in yeast 
Schizosaccharomyces pombe and the human homolog RAD17 has been also 
identified and characterised66, 67. It is thought to be a critical early sensor protein 
through which DNA damaging insults activate the ATR dependent signal cascade 
that lead to cell cycle arrest and DNA repair68. RAD17 is part of the RAD17-RFC 
(complex of Rfc1-5 subunits) complex which binds to single strand DNA (ssDNA) 
structures69. Acting as a clamp loader, RAD17 loads the complex Rad9-Hus1-Rad1 
(9-1-1 complex) onto DNA damage sites, an event that potentially create a 
chromatin location site for 9-1-1- sliding clamp to interact with other elements of 
the checkpoint machinery and facilitates ATR-dependent phosphorylation of 
downstream targets to fully activate the DNA damage response68 (Figure 6).  
 
Figure 6: Schematic illustration of RAD17 protein function in the activation of DDR 
When damage occurs, ssDNA at sites of damage is coated by Replication protein A (RPA) 
important event for the recruitment of ATR (ataxia-telangiectasia and Rad3-related) 
through a direct interaction with ATRIP (ATR interacting protein). At this point, the Rad17 
clamp loader load the 9-1-1 (Rad9-Hus1-Rad1) checkpoint clamp onto the junction of the 
ss/dsDNA (single strand/double strand DNA), event that promote the recruitment of 
TopBP1, an ATR kinase activator, that culminate in the activation of ATR kinase and in the 
phosphorylation of the Chk1 (checkpoint kinase 1), facilitated by claspin, for signal 
transduction. Image from Mohni KN et al70. 
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Beside the role of RAD17 in the ATR signalling, it has been recently shown that 
RAD17 is required for early ATM kinase activation and consequent ATM-mediated 
phosphorylation of downstream targets which promote HRR71 . The proposed role 
for RAD17 is the early recruitment and maintenance at damage sites of the MRN 
(Mre11-Rad50-Nbs1) complex thus allowing ATM activation by phosphorylation and 
subsequent phosphorylation of ATM targets (Figure 7), which are the essential steps 
for the detection of DSBs and initiation of DNA damage signalling cascade71. 
 
Figure 7: Illustration of the possible role of RAD17 in the ATM signalling pathway 
RAD17 play a role also in the ATM pathway by helping in the recruitment and retention at 
the sites of DNA damage of the MRN complex (upper panel). In this way, it would promote 
the phosphorylation mediated by ATM of downstream targets such as γH2AX and Mdc1 
amplifying the ATM-dependent DNA damage signalling cascade leading to homologous 
recombination repair. Image adapted from Paull TT and Lee JH72. 
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1.3.2 RAD17 and cancer 
The dysregulation of RAD17 was found to be associated with different types of 
tumours73-76; moreover RAD17 is located on chromosome 5q13.2, a region known to 
be deleted in a variety of human cancers77-79. For example, Ming Zhao et al 
identified loss of RAD17 expression, often due to genomic deletion, to be associated 
with genome instability in head and neck cancer73. On the other hand, an 
overexpression status of the RAD17 protein was detected in colon carcinoma 
compared to normal tissues by Bao S and colleagues74. Overexpression of the 
RAD17 gene was also identified to be associated with lymph node metastasis in 
breast and non-small cell lung cancers75, 76. Fredebohm and colleagues conducted a 
synthetic lethal RNAi screen and identified depletion of RAD17 to be linked with an 
increased sensitivity of pancreatic cells to gemcitabine80. Interestingly Shen and 
colleague identified RAD17 Knockdown as synthetically lethal with Checkpoint 
kinases inhibition in HeLa and LN428 cell lines81. Since its role in activating the DNA 
damage response and its altered expression in cancer cells, RAD17 represents a 
suitable target to be regulated in order to potentially obtain sensitisation to 
chemotherapy and DDR targeted therapy. 
1.3.3 DDR and cancer  
The DNA damage response is a complex signalling network, essential for 
maintaining the genomic integrity of the cell, and its disruption is one of the 
hallmarks of cancer82. Indeed proteins involved in DDR are frequently mutated or 
abnormally expressed in cancer cells83. Compared to normal cells, cancer cells often 
display defects in one or more DDR pathways leading to a higher dependency on 
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the remaining repair pathways26. One example is mutation in the TP53, the guardian 
of the genome, which is a common feature of late stage tumours and is responsible 
for tumour susceptibility13, 84. Upregulation of DDR factors such as Chk1, Chk2, 
RAD50 or NBS1 has been reported in several cancer types, while mutation or 
reduced expression of protein such as ATM RAD51 or BRCA1 has been also 
observed as reviewed by Hosoya and colleagues85. In particular in ovarian cancer 
mutations in BRCA1 and BRCA2, critical effectors proteins of the HR pathway are 
associated with tumorigenesis. Also mutations in ATM or RAD51 genes were found 
to correlate with hereditary ovarian cancer and increased risk of disease86, 87. 
1.3.4 DDR and targeted therapy 
Cancer cells display a major susceptibility to DNA-damaging agents compared to 
normal cells due to their DDR and DNA repair-deficiency. This feature of cancer cells 
can be used as a therapeutic opportunity by targeting protein components of the 
DDR system88, 89. For this reason, several DDR targeted therapies have been 
developed in the last 10 years in order to achieve what is defined as synthetic 
lethality. This approach is based on the concept that targeting two or more cancer 
relevant genes lead to cell death, whereas perturbation of only one does not. Such 
a mechanism provides significant patient benefit, enabling normal cells with a 
functional DDR to remain unaffected reducing general toxicity90. The best example 
of targeting DDR in a synthetic lethal way is probably the use of PARP inhibitors for 
BRCA1/2 mutated cancer cells91, 92. PARP1 is an enzyme that detects and binds to 
DNA SSBs initiating DNA repair by a variety of mechanisms such as BER and NER93, 94. 
Inhibition of PARP1 enzymatic activity causes the failure of SSBs lesions to be 
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repaired, resulting in their accumulation and conversion to deleterious DSBs that 
require HRR to be repaired and therefore functional BRCA1/2. Indeed, BRCA1/2 play 
a critical role in HRR facilitating the recruitment of RAD51 at ssDNA sites, a key 
molecule for homologous strand exchange in HRR pathway. Inactivating mutations 
of BRCA1/2 in cancer cells therefore cause severe defects in HRR and simultaneous 
inactivation of PARP1 enzymatic activity renders impossible the DNA repair thus 
causing cell death95, 96 (Figure 8). Of note, the PARP inhibitor olaparib, was recently 
approved by Food and Drug Administration (FDA) and European Medical Agency 
(EMA) as maintenance monotherapy for recurrant, platinum sensitive ovarian 
cancer patients bearing germline BRCA1/2 mutations97, 98 and represents one of the 
best examples to date of personalized therapy for ovarian cancer99,100, 101. 
 
 
Figure 8: Synthetic lethality induced by Inhibition of PARP1 enzymatic activity. 
In normal cells, DNA damage is repaired by different DDR pathways, such as base-excision 
repair mediated by PARP1 activity, and homologous recombination mediated by BRCA 
proteins function (left panel). In cancer cells with mutation in BRCA1 or BRCA2, homologous 
recombination is non-functional and when PARP1 is inhibited, both base-excision repair and 
homologous recombination pathway are no more available and cells are committed to 
death (right panel). Image adapted from Iglehart JD et al102. 
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Besides homologous recombination, also targeting replication stress, another 
hallmark of cancer103, can be of great value. Replication stress, typically occurring 
during DNA replication, is characterised by generation of stalled replication forks 
and induction of a DDR in order to stabilize them to prevent replication forks 
collapse and generation of cytotoxic DNA DSBs104. Both ATR-Chk1 pathway and 
Wee1-CDK1/2 pathway are important regulators of replication stress thus 
representing attractive DDR targets105, 106. Several inhibitors of these molecules are 
currently being investigated in clinical trials such as inhibitors of ATR (AZD6738, 
VX970), Chk1 (LY2606368, MK8776) and Wee1 (AZD1775) also in the context of 
EOC107. 
1.3.5 Combining DDR inhibitors with DNA damaging drugs 
Platinum agents (cisplatin, carboplatin), alkylating agents (temozolomide) and 
inhibitors of topoisomerase (topotecan, irinotecan, doxorubicin) are commonly 
used DNA damaging drugs and interesting data on combination with DDR inhibitors 
has been presented in preclinical83, 108, 109 and clinical studies110 thus representing 
important opportunities for cancer therapy. Importantly it has been observed that 
combinatorial strategies can re-sensitise resistant tumours as in the case of 
platinum resistant lung cancer patients which displayed a re-sensitisation to 
platinum treatment when exposed to the Wee1 inhibitor AZD1775 110. Moreover 
DDR-DDR agent combinations are being tested and several clinical trials are 
underway107 as in the case of the combination of PARP inhibitor and Wee1 inhibitor 
(Clinicaltrials.gov ID NCT02272790). However, successful combination of DDR 
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inhibitors or DDR inhibitors and DNA damaging drugs will depend on the right 
association of cancer genetic background with the specific DDR dependency. 
1.4 MicroRNAs 
1.4.1 Biogenesis and role of miRNAs as regulator of gene expression 
MicroRNAs (miRNAs) are a class of endogenously expressed non-coding RNA, with a 
length of 19–25 nucleotides, discovered over two decades ago, now recognized as 
one of the major regulators of gene expression111. Thousands of different miRNAs 
have been identified in animals and plants, and more than 2500 in humans as 
documented in the Sanger miRBase sequence database (http://www.mirbase.org). 
A large number of miRNAs are conserved in closely related species and many have 
homologs in distant species, suggesting that their function could also be conserved 
throughout evolution112. RNA polymerase II transcribes microRNA molecules from 
genomic DNA into a primary microRNA molecule (pri-miRNA). Pri-miRNA molecules 
that contain a stem-loop structure are recognized by the RNAse III DROSHA and its 
partner protein DGCR8, which cuts the double-stranded RNA into ~70-nucleotide 
precursor microRNA (pre-miRNA) in the nucleus. Pre-miRNA molecules are exported 
to the cytoplasm by exportin-5 and are processed by DICER, an RNAse III, into two 
unique single-stranded mature microRNA molecules representing each side of the 
stem loop structure. Mature microRNA molecules are loaded onto the Argonaute-
containing RNA-induced silencing complex (RISC). Within this structure, mature 
microRNA molecules function to repress gene expression by complementary 
binding of the 3′ untranslated region (UTR) of the target gene to the miRNA seed 
sequence, constituted by nucleotides 2–8 of the mature miRNA molecule, leading to 
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transcript degradation or translation inhibition depending on the level of 
complementarity113 (Figure 9).  
Figure 9: Biogenesis of miRNAs and their regulatory function in cells Image from  
Barca-Mayo O and Lu QR114. 
 
1.4.2 MicroRNA and cancer  
Each miRNA has multiple target genes and regulate different physiologically 
important processes in the body, such as cell proliferation, differentiation, 
metabolism, regulation of immune response and cell cycle resulting very important 
in maintaining the integrity of a cell. Moreover the same target gene can be 
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influenced by multiple miRNAs, so it is not surprising that abnormalities in their 
expression are implicated in the pathogenesis of several diseases including 
cancer115-117. Global alteration in miRNA expression patterns was identified in cancer 
cells compared to normal tissues linking miRNA deregulation to tumorigenesis118. 
Deregulated miRNA expression can be partially attributed to genomic alterations in 
miRNA loci and in miRNA copy number variations. Indeed miRNAs often maps in 
particular genomic regions prone to alteration in cancer as fragile sites or region 
with high frequency of LOH (loss of heterozigosity), deletion and amplification 
events contributing to their deregulation116, 119. First evidences of these genomic 
alterations were for example the loss of miR-15a/16 cluster region at chromosome 
13q14 in B-cell leukemia120 or the amplification of miR-17–92 cluster gene in B-cell 
lymphomas and lung cancer121, 122.  
Upregulations and downregulations of different miRNAs have been identified as 
critical for various aspects of tumorigenesis, from transformation to metastatic 
events and dissemination and chemoresistance mechanisms of many cancers. 
Several studies correlated miRNA expression with different tumour types and their 
expression is often exclusively of specific tissue type. MiRNAs acting as key 
regulators of gene expression can be classified as tumour suppressor miRNAs or 
oncomiRNAs based on their function in regulating tumour phenotype116, 123. For this 
reason miRNA expression profiles provides an additional layer of information 
compared to the mRNA profiles, thus increasing the accuracy for tumour diagnosis 
and improving prediction of therapeutic responses and overall survival (OS) of 
cancer patients.  
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1.4.3 MicroRNA and EOC  
Most of publications focusing on miRNAs in EOC have been published in the last 5 
years indicating the increasing interest in defining their role in this malignancy. The 
possibility to better define miRNA-driven mechanisms regulating EOC phenotype 
represents an exciting opportunity in EOC cancer therapeutics. Several miRNA 
profiling studies discovered aberrant expression of miRNAs associated with EOC 
tumorigenesis and progression, providing improved diagnostic, prognostic and 
therapeutic approaches124-126. A general downregulation trend of miRNA expression 
in EOC compared to normal counterpart has been observed by different authors 
and similar set of dysregulated miRNAs were identified. In a study performed by 
Iorio and Croce127 using ovarian cancer tissues and cell lines compared to normal 
counterpart (normal ovarian tissues sample), 25 out of 29 dysregulated microRNAs 
were found to be downmodulated, and 4 microRNAs were found to be 
upmodulated. The overall miRNA expression was able to differentiate normal versus 
tumour samples. Zhang and collaborators128 found a similar trend of significantly 
differentially expressed microRNAs with 31 out of 35 miRNAs downregulated in EOC 
cell lines compared to IOSE (immortalized ovarian surface epithelium) cells. 
Furthermore a trend of downregulation of differentially expressed miRNA was 
observed in late compared to early stages and in high compared to low-grade 
EOC128. In addition, miRNAs differentially expressed in omental secondary lesion 
compared to primary tumour were found to be responsible of increased cancer 
cells’ survival and drug tolerance129 suggesting the important role of miRNAs both in 
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the disease progression and response to therapy. Data in the table list the principal 
dysregulated miRNAs in ovarian cancer (Table 1). 
Table 1: miRNAs found to be consistently dysregulated in ovarian cancers compared to 
different normal counterpart (adapted from Zhang S et al77). 
 
Alteration miRNAs Counterpart Effect Mechanism of Deregulation Targets 
Down-
regulated 
Let-7a/b/d/f 
OSE, IOSE, ovary, fallopian 
tube from fimbriated end 
tumour 
suppressor 
promoter methylation, copy 
number variations  
KLK10, HMAG2 
miR-22 OSE 
tumour 
suppressor 
  
ARRB1, CLIP2, 
EVI1,FRAT2, EDC3 
miR-31 OSE 
tumor 
suppressor 
copy number variation E2F2, STK40, CEBPA 
miR-34a/b/c 
 IOSE, ovary, fallopian tube 
from fimbriated end 
tumour 
suppressor 
promoter methylation, copy 
number variations and TP53 
mutations  
MET, CDK4 
miR-125b 
OSE, IOSE, ovary, fallopian 
tube from fimbriated end 
putative tumour 
suppressor   
BCL3,VEGF,HIF-1α,HER3 
miR-127-3p OSE, NOSE, ovary, serum 
related to drug-
resistant 
imprinting, copy number 
variations, promoter methylation 
 
miR-152 
OSE, IOSE, fallopian tube 
from fimbriated end 
putative tumour 
suppressor 
promoter methylation 
  
miR-155 IOSE, blood, serum 
putative tumour 
suppressor     
miR-181a-3p OSE, ovary, blood 
  
copy number variations, promoter 
methylation   
miR-382 HOSE 
  
copy number variations, promoter 
methylation 
  
Up-
regulated 
miR-15a/16 
OSE, fallopian tube from 
fimbriated end 
  
promoter methylation Bmi-1 
miR-20a 
OSE, fallopian tube from 
fimbriated end 
oncogenic 
miRNA   
APP 
miR-23a/b ovary 
  
copy number variations, promoter 
methylation   
miR-30a/b/c 
OSE, IOSE, fallopian tube 
from fimbriated end 
related to drug-
resistant 
copy number variations AVEN, GALNT1 
miR-92 
OSE, fallopian tube from 
fimbriated end 
putative 
oncogenic 
miRNA     
miR-93 ovary 
putative 
oncogenic 
miRNA 
copy number variations, promoter 
methylation 
  
miR-106a 
OSE, fallopian tube from 
fimbriated end 
putative 
oncogenic 
miRNA 
    
miR-146b 
OSE, IOSE, fallopian tube 
from fimbriated end 
putative 
oncogenic 
miRNA 
copy number variations   
miR-182 
OSE, IOSE, ovary, fallopian 
tube from fimbriated end 
putative 
oncogenic 
miRNA 
copy number variations, promoter 
methylation 
PDCD4 
miR-200 
OSE, ovary, fallopian tube 
from fimbriated end 
putative 
oncogenic 
miRNA 
copy number variations 
ZEB, c-Myc,TUBBIII,FN1, 
NTRK2,QKI 
miR-203 
OSE, ovary, fallopian tube 
from fimbriated end 
  promoter methylation   
miR205 
OSE, ovary, fallopian tube 
from fimbriated end 
putative 
oncogenic 
miRNA 
promoter methylation   
miR-223 OSE 
putative 
oncogenic 
miRNA 
  SEPTIN6, MMP9, USF2 
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1.4.4 MiRNAs as early diagnostic, prognostic and predictive biomarkers in EOC 
The lack of reliable biomarkers for EOC early diagnosis, prognosis or for monitoring 
drug response during chemotherapy, and the lack of reliable patients’ stratification 
strategies before starting treatment, represent gaps to be covered in order to 
improve success in treating EOC. It is now emerging that microRNAs are good 
candidates to be taken into account to achieve this goal. They maintain stability also 
in formalin fixed tissues, which represent the commonest source of samples for 
biomarkers analysis, and are also abundantly present in body fluids such as blood, 
where they can circulate and regulate the gene expression of recipient cells130, 131. 
Many studies showed that the blood miRNAs of patients affected by various 
diseases is altered compared to that of healthy subjects132-134. MiRNAs in the blood 
stream are resistant to degradation by RNAse enzymes and are high stable135, 136, 
since they are complexed with proteins such as Ago2 (Argonaute 2) or are 
transported by vesicles such as exosomes137. For all these reasons, circulating 
miRNAs represent minimally invasive promising category of early diagnostic 
markers also for EOC138. Dysregulated expression of microRNAs at tissue level as 
potential prognostic and predictive markers has been also deeply investigated in 
recent years. MiR-200 family members, known epithelial to mesenchymal transition 
(EMT) regulators, are deregulated in ovarian cancer as reported by several 
authors127, 139 and their expression correlate with progression-free survival (PFS) and 
OS in EOC patients. In particular, in stage I EOC low expression level of miR-200c 
was shown to be an independent prognostic factor of poor survival and a biomarker 
of disease relapse by Marchini and collaborators140. Let-7b, was reported to be an 
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unfavourable prognostic biomarker in HGSOC and was able to stratify patients in 
distinct risk groups with different survival rate141. Calura et al performed a study on 
203 early stage snap-frozen EOC samples, collected at surgery, showing that a 
miRNA signature, combined with a gene expression profile, was able to provide a 
prognostic cell pathway, composed of 16 miRNAs and 10 genes, that was associated 
with OS and progression free survival PFS142. Another important prognostic model 
was developed and validated by my research group analyzing the miRNA expression 
profile of 894 EOC samples, the largest EOC collection so far available, with the aim 
of identifying a miRNA signature associated with progression and relapse. A 
signature based on 35 miRNAs, MiROvaR (miRNA-based predictor of Risk of Ovarian 
Cancer Relapse or progression), was developed143. This signature was able to predict 
the risk of progression or early relapse in EOC, allowing patient stratification into 
low- and high-risk groups, with a difference in the median progression-free survival 
of 20 months between the high-risk and low-risk groups. MiROvaR maintained its 
prognostic independency when adjusted for stage and residual disease, the two 
most important clinical prognostic factors in EOC. Among microRNAs that most 
contributed to MiROvaR and found to be downregulated in the group with high risk 
of relapse there were the miR-200 family and the miR-506 family. Interestingly we 
previously reported the miR-506 family to be downregulated in early relapsing 
advanced stage EOC patients144 and we contributed with other groups to show that 
miR-506 is involved in EMT process145, tumour proliferation146 and chemotherapy 
response147. Overall, these studies strengthen the role and the ability of miRNAs in 
stratifying patients into risk classes. Furthermore both Calura’s and Bagnoli’s 
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studies142, 143 showed that the prognostic role associated with their miRNA 
signatures is independent from histological subtype, further supporting the use of 
miRNAs as prognostic biomarkers in EOC. 
1.4.5 MiR-506 
We previously identified a cluster of eight miRNAs mapping on the chromosome X 
in the q27.3 region (ChrXq27.3 cluster) whose down-regulation is independently 
associated with early relapse in advanced stage high grade EOC patients144. MiR-506 
belongs to this cluster and it represents the most investigated among the family and 
probably the driver miRNA of the cluster, being a key node in regulating EMT in 
EOC. MiR-506 functional and biological characterization revealed its involvement in 
regulation of both cell plasticity and drug response to chemotherapy145, 148. 
Furthermore, many different studies so far demonstrated the tumour suppressor 
role of miR-506 across different tumour types149-152 through regulation of different 
target genes involved in several biological processes such as cell growth, migration 
and invasion, apoptosis and chemoresistance (Figure 10). 
Interestingly miR-506 and the other microRNAs of the ChrXq27.3 cluster are all 
included in the MiROvaR predictor identified by my research group further 
supporting its important role in EOC and our interest in better define its 
contribution to this aggressive disease. 
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Figure 10: Tumour suppressive role of miR-506 on different biological processes 
Mir-506 is often downregulated in various types of cancer and putative binding sites of 
transcription factors have been identified upstream of miR-506 gene. Acting as a tumour 
suppressor miRNA, it regulates important genes involved in different cellular processes, 
such as ROCK1, N-RAS, VIM, RAD51, CDK4/6. Image from Li Jet al 2016153. 
 
-MiR-506 in ovarian cancer 
Many studies have shown the important role of miR-506 in regulating important 
cellular processes in ovarian cancer. We reported that miR-506 reintroduction was 
able to inhibit cell proliferation and increase cell sensitivity to platinum treatment in 
EOC cell lines144. Yang D and collaborators showed that miR-506 through direct 
targeting of SNAI2, a transcriptional repressor of the epithelial phenotype marker E-
cadherin, inhibited cell migration and invasion, induced E-cadherin expression and 
was able to abolish a TGF-β induced mesenchymal phenotype in EOC cellular 
models148. Moreover miR-506 suppresses other components of the EMT network, 
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Vimentin and N-cadherin, two important mesenchymal markers, thus inducing a 
reversion versus a more epithelial and less aggressive phenotype145. An anti-
proliferative effect of miR-506 was shown by the same authors on EOC cells due to 
the suppressive effects on the CDK4/6-FOXM1 signalling pathway, usually activated 
in serous EOC. By a direct targeting of CDK4 and CDK6, cyclin-dependent kinases 
involved in cell cycle progression, miR-506 promoted cell senescence146. 
Due to the increasing evidences of the involvement of EMT in EOC 
chemoresistance154-156, we contributed with Liu G and colleagues to unravel the role 
of miR-506 in chemoresponse showing that miR-506 is associated with a better 
response to therapy and longer PFS ad OS in high grade ovarian cancer. MiR-506, 
through direct targeting of RAD51, involved in double strand DNA (dsDNA) repair 
through HRR process, is able to sensitise cells to platinum and PARPi olaparib 147. All 
these findings support the important role of miR-506 as tumour suppressor in 
ovarian carcinoma. 
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2. Aims of the Project 
Despite optimal surgery and chemotherapy, the majority of EOC patients 
experience relapse of the disease. Thus a major challenge in EOC remains prediction 
of chemoresistant relapse and definition of mechanisms of chemoresistance. 
MiRNAs are considered important tools through which to obtain a molecular 
portrait of EOC chemoresistance and represent possible therapeutic targets to be 
used in the clinic. We previously identified the ChrXq27.3 miRNA cluster as 
downregulated in early relapsing advanced stage EOC patients and we defined miR-
506, belonging to the ChrXq27.3 miRNA cluster, as potentially relevant as regulator 
of EOC cellular plasticity and response to therapy. 
Thus this thesis aimed to dissect the miR-506-driven molecular mechanisms 
involved in regulating response to chemotherapy by: 
1. Investigating the potential role of miR-506 in the response to chemotherapeutic 
treatments and identifying possible miR-506 targeted genes involved in chemo-
response; 
2. Define the miR-506-driven molecular mechanisms at the basis of chemo-
response. 
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3. Materials and Methods 
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3.1 Cell biology technique 
3.1.1 Cell Cultures  
Human ovarian carcinoma cell lines 
Several EOC cell lines, resembling tumour heterogeneity, and their characteristics 
are listed in Table 2. 
 
Table 2: Ovarian cancer cell lines 
Cell lines Histology TP53 mutational status Source 
OAW42 SEROUS WT 
Dr. Ullrich, Max-Plank 
Institute of 
Biochemistry, 
Martinsried, Germany 
SKOV3 
ENDOMETRIOID/CLEAR 
CELL 
NULL ATCC 
A2774 ENDOMETRIOID  MUT ATCC 
IGROV1 MIXED  MUT 
Dr. J. Bernard, Institute 
G. Roussy, Villejuif, 
France. 
OVCAR3 HIGH GRADE SEROUS MUT ATCC 
OVCAR5 SEROUS NULL Dr.R. Camalier, NCI, 
Frederick, MD 
OVSAHO HIGH GRADE SEROUS  MUT 
Dr. Baldassarre, CRO 
Aviano,Italy 
COV362 HIGH GRADE SEROUS MUT 
Dr. Baldassarre, CRO 
Aviano,Italy 
A2780 
ENDOMETRIOID/CLEAR 
CELL 
WT ECACC 
WT: wild type; MUT: mutated. ATCC: American Type Culture Collection; ECACC: 
European Collection of Cell Culture. Histological types are reported as described  157 
 
Besides the EOC cell lines the following were used: HEK293T (ATCC), a human cell 
line isolated from human embryonic kidneys (HEK) was used for luciferase assays. 
A431 (epidermoid carcinoma), H460 (non small cell lung cancer), PC3, DUI45, LNCAP 
(prostate cancer), MDA-MB-468, MCF-10 (breast cancer), and HCT-116 (colon 
cancer) cancer cell lines were used for RNA extraction and real time PCR 
experiments. All human cell lines used in this thesis were cultured at 37°C with 5% 
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CO2  and maintained in RPMI 1640 (Lonza) supplemented with 10% heat-
inactivated fetal bovine serum (FBS) (Gibco®, life technologies) and 2 mM L-
glutamine (Sigma-Aldrich, St. Louis, MO, USA) except for OAW42 which was 
maintained in MEM (Gibco®, life technologies) supplemented with 10% heat-
inactivated FBS 2mM L-glutamine and 1% non-essential amino acids (100X stock; 
Euroclone, Italy), HEK293T in DMEM (Gibco®, life technologies), supplemented with 
10% heat-inactivated FBS and 1% glutamine and OVCAR3 which was maintained in 
RPMI supplemented with 20% heat-inactivated FBS 2mM L-glutamine and 1% 
sodium pyruvate. 
Cells were confirmed to be mycoplasma-free using MycoAlertPlus detection kit 
(Lonza) and subjected to short tandem repeat (STR) DNA profiling in accordance 
with the ATCC guidelines, and the genetic profiles were compared with those of 
publicly available databases to verify their authenticity. Analysis was performed by 
our Genomic Facility at INT, Milan. 
3.1.2 Drug used and treatments 
Cis-diamminedichloroplatinum (DDP) (Teva Pharmaceuticals Industries Ltd) (3.3 
mM) was used at doses ranging from 0.1 to 100 µM depending on the cell line used. 
The PARP inhibitor (PARPi) olaparib (selleckchem.com) was reconstituted in 
dimethyl sulfoxide (DMSO) to a concentration of 10 mM and stored at -20°C. It was 
used at doses ranging from 0.5 to 10 µM depending on the cell line used. 
The Chk1 inhibitor LY2603618 (selleckchem.com) was reconstituted in DMSO to a 
concentration of 10 mM and stored at -20°C. It was used at doses ranging from 50 
to 300 nM depending on the cell line used. 
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The Wee1 inhibitor AZD1775 (Biovision Inc. Milpitas, CA; USA) was reconstituted in 
DMSO to a concentration of 100 mM and stored at -20° C. It was used at doses 
ranging from 0.25 to 200 nM depending on the cell line used. 
For short term cell survival assays cells were plated in 96 wells at the concentration 
of 2500-5000 cells per well depending on the cell type. Then platinum titration 
curves were obtained by treating cells (n=6 wells per treatment) for 7h, and effects 
observed after 72h. Control cells were treated with appropriated medium.  
For clonogenic assays cells were plated in 6 wells at the concentration of 1000 cells 
per well. Drug titration curves were obtained by treating cells (n=3 well per 
treatment) with different drugs for 10-14 days. Control cells were treated with 
appropriated medium. 
3.1.3 Transient transfection 
Transfection experiments in this thesis include: 
 miRNA transfections, into the cells to examine their biological effects on cell 
function; 
  miR-target protector (TP) transfection, to protect a single miRNA target 
gene; 
  siRNA transfections, to reduce mRNA and protein levels of a target gene; 
  plasmid transfections, for luciferase assay.  
All the transfections were performed with liposome-mediated methodology using 
Lipofectamine® 2000 (Thermo Fisher Scientific) and Opti-MEM (Gibco®, life 
technologies), a specific medium with reduced serum, or serum-free media. 
Transfection was performed with suspended cells with Lipofectamine® 2000 used at 
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a ratio of 1:1 with exogenous nucleic acid and, after 15’ incubation at room 
temperature (RT) to allow lipidic incorporation of exogenous nucleic acid, the 
transfection mix was added to the cells and incubated at 37°C, in a 5% CO2 
incubator for 4.5 hours. Transfection mix was then removed by centrifugation and 
complete medium added. Cells were seeded and allowed to grow at 37°C, in a 5% 
CO2 incubator for the appropriate amount of time before the subsequent 
treatment. 
MiRNAs transfection was performed with 60 nM per 105 cells of mirVANA miRNA 
mimic and negative scramble miR (Thermo Fisher Scientific). To evaluate 
transfection efficiency, a real-time PCR for transfected miRNA was carried out at 
48/72h post transfection. 
SiRNA transfection was performed with 60 nM per 105 cells of siRNA molecules 
(siGENOME Smart Pool small interfering RNA) or non targeting siRNA used as 
control (Dharmacon Inc, Horizon Discovery Group plc). SiRNA mediated knock-down 
of target gene and protein was checked 48h/72h after transfection by qRT-PCR and 
western blot analysis, respectively. 
-Co-transfections 
In case of simultaneous transfection of miRNAs and DNA, cells were first transfected 
with miRNAs following the protocol described above and 24h later transfected with 
DNA (pmirGLO vector plasmid at the concentration of 0.5 µg per 105 cells) used for 
luciferase assays. In the case of simultaneous transfection of miRNAs and miScript 
Target Protectors (QIAGEN), a co-transfection was performed using 60 nM of both 
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for 4.5 hours. Successful transfection of miRNAs and TP in the cells were checked at 
both protein and mRNA level by western blot and qRT-PCR assays respectively. 
3.1.4 Clonogenic assay 
Clonogenic assay is an in vitro cell survival assay used to measure response to 
chemotherapeutic agents. After transfection/silencing according to the type of 
experiment, cells were seeded in six-well plates in triplicate at the concentration of 
1000 cells per well. Cells were then exposed to drug treatments, and the ability of a 
single cell to grow into a colony was evaluated after 10-14 days. Colonies were 
gently washed with PBS 1X, fixed with ice-cold methanol (stored at -20°C) for 10 
min on ice, stained with 0.5% Crystal violet solution (Sigma-Aldrich, St. Louis, MO, 
USA) for 10 min at RT and washed with ddH2O for colony visualization. Colonies 
with more than 50 cells were counted using an optical microscope. 
 
3.1.5 Test of cell viability and proliferation assays 
-Trypan blue exclusion assay 
Cell viability was assessed by trypan blue exclusion staining. Cell suspension was 
mixed in a 1:1 ratio with trypan blue (Sigma-Aldrich, St. Louis, MO, USA) and 
counted with an optical microscope using a boyden chamber. An automated cell 
count was also performed using a Countess® Automated Cell Counter (Invitrogen) 
mixing 10 µL of sample with 10 µL of trypan blue stain (0.4%), and pipetting 10 µL of 
the suspension mix into a disposable Countess® chamber slide.  
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-CellTiter-Glo® Luminescent Cell Viability Assay 
The effect on cell growth was assessed using a CellTiter-Glo® Luminescent cell 
viability assay (Promega Corporation, Madison, USA), that measure ATP generated 
by metabolically active cells, following manufacturer's instruction. Briefly, 
2500/5000 cells per well, depending on the cell line used, were plated in sterile 96-
wells in complete medium. At the end of the 100 μL of CellTiter-Glo® reagent was 
added to cells left in 100 μL of medium for cell lysis. After 10 min incubation at 
room temperature, the luminescence was recorded in a luminometer (TecanUltra, 
Tecan trading AG, Switzerland). The luminescence signals for treated cells were 
normalized by the luminescence signal obtained from control cells according to 
specific experimental design. 
 
3.1.6 Cell cycle analysis by flow cytometry 
Cell cycle analysis by flow cytometry is a method that allow researcher to 
distinguish cells in different phases of the cell cycle according to their DNA content. 
Propidium Iodide (PI) is a fluorescent dye that stains DNA quantitatively and the 
relative DNA amount of cells in the different phases (G0, G1, S, G2 and M) can be 
determined. Cells were collected, washed with PBS 1X and fixed in 700 µL of 70% 
cold ethanol for at least 30 min at 4°C. Fixed cell were then centrifuged at 2000 rpm 
for 5 min and washed once with PBS 1X, in order to remove ethanol. Pellet was then 
resuspended in 100 µL of PBS 1X-Ribonuclease-A (Sigma-Aldrich, St. Louis, MO, USA) 
100 ug/ml and incubated at RT for 10 to 30 min to degrade RNA molecules. DNA 
was stained with PI 50 ug/ml for 10 min before analysis. Cell cycle was determined 
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using a BD LSRII Fortessa instruments (BD Biosciences, Franklin Lakes, NJ) and 
results analysed using FlowJo software (Tree Star Inc, Ashland, OR). 
 
3.2 Biochemical techniques 
3.2.1 Cell lysis and assessment of protein concentration 
Cells were left to grow until desired confluence, then washed once in ice-cold 
PBS/sodium orthovanadate (0.1 mM), lysed with appropriate volume of lysis buffer 
(10 mM Tris-HCl pH8.0, 1 EDTA 0.5 mM, EGTA 0.1%, SDS 0.1%, Deoxycholic acid 140 
mM, NaCl 1%, Triton X-100, H2O, proteases/phosphatases inhibitor cocktails (1 tab 
in 10 mL of lysis buffer) (Roche, Italy) at 4°C for 30 min, and then centrifuged at 
13000 rpm for 5 min at 4°C. Whole cell lysates were normalized for protein 
concentration using bicinchoninic acid (BCA) protein assay reagent according to the 
manufacturer’s instructions (Pierce, USA). BSA (1 mg/ml) was used to prepare 
protein standards. Absorbance at 562 nm was measured using a 
spectrophotometer. Protein concentration was determined against the BSA 
standard curve. Alternatively cells were washed once with ice-cold PBS/sodium 
orthovanadate (0.1 mM) (Sigma-Aldrich, St. Louis, MO, USA) and then lysed with 
NuPAGE™ LDS Sample Buffer (1X) (Thermo Fisher Scientific, Waltham, MA, USA) 
diluted in dH2O plus β-Mercaptoetanol 0.1% (Sigma-Aldrich, St. Louis, MO, USA), 
that provides the optimal conditions for reduction of protein disulfide bonds and 
denaturation. Samples were analysed immediately or stored at -20°C for future 
analysis. Before loading into polyacrylamide gel, samples were boiled at 95°C for 5 
min. 
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3.2.2 SDS-PAGE 
SDS-PAGE (Polyacrylamide gel electrophoresis) was performed using the NuPAGE™ 
electrophoresis system (Thermo Fisher Scientific) with pre-casted NuPAGE™ Novex 
gels. Based on the molecular weight of proteins to be separated, different types of 
pre-casted gels were used: 3-8% polyacrilamide Tris-Acetate gels and 4-12% 
polyacrylamide Bis-tris gels. Run was performed at 100 V with specific buffers (Tris-
Acetate for 3-8% gels and 3-N-morpholino propanesulfonic acid (MOPS) for 4-12% 
gels). Novex™ Sharp or SeeBlue™ Plus2 Pre-stained Protein Standards (Thermo 
Fisher Scientific), were used as protein molecular weight marker; 500 µL of 
NuPAGE™ antioxidant (Thermo Fisher Scientific) were added to the running buffer 
in order to protect disulfide bonds from oxidation. 
3.2.3 Western blot 
After SDS-PAGE, proteins were transferred to nitrocellulose membrane using 
iBlot2TM Dry Blotting System (Invitrogen) consisting of the iBlot2TM Gel Transfer 
Device and associated iBlot™ 2 Transfer Stacks that have integrated the 
nitrocellulose transfer membranes. Transfer of protein was carried out in 7 min at 
20-25 Volts. After transfer the membrane was stained with Ponceau Red (Sigma-
Aldrich, St. Louis, MO, USA) to verify efficiency of transfer, then rehydrated with 
Tris-buffered saline with Tween 20 (TBS-T) buffer [20 mM Tris, 150 mM NaCl, pH 
7.6, 0.1% Tween 20] and saturated with milk (skim milk powder, Merck Millipore) to 
prevent non-specific interactions between the membrane and the detecting 
antibodies. Membranes were incubated overnight at 4°C with 5 ml of the 
appropriate antibody diluted in TBS-T or non-fat dry milk as specified by antibody 
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datasheet. After hybridization with primary antibody, membranes were washed 
three times with TBS-T for 5 min and incubated for 30’-60’ RT with the peroxidase- 
or biotin- conjugated secondary antibodies (GE healthcare) from rabbit (1:200 
dilution), mouse (1:1000 dilution) or goat (1:1000 dilution) depending on the source 
of the primary antibody. Signal was revealed using a ChemiDoc XRS system and the 
ECL chemoluminescence system (BIO-RAD, Hercules, CA, USA). Quantity One® 
software (BIO-RAD, Hercules, CA, USA) was used for quantification of band 
intensities. Membranes were then treated with a stripping solution (Restore™ 
western blot stripping buffer (Thermo Fisher Scientific) for 15 min at 37°C to allow 
further hybridizations with other antibodies. Antibodies used are listed in Table 3. 
 
Table 3: List of the antibodies used 
Antibody Clone and catalog N Supplier 
VINCULIN E1E9V 13901 Cell Signaling TECHNOLOGY®, Danvers, MA,USA 
β-ACTIN A2066 Sigma-Aldrich, St Louis MO, USA 
RAD17 R8654 Sigma-Aldrich 
RAD51 H-92: sc-8349 Santa Cruz, CA, USA 
CHK1 2G1D5 2360 Cell Signaling TECHNOLOGY®, Danvers, MA,USA 
pCHK1(S296) D309F 90178 Cell Signaling TECHNOLOGY®, Danvers, MA,USA 
γ-H2AX A300-081A-M Bethyl Laboratories, Inc, Montgomery, TX, USA 
ATM Y170 ab32420 Abcam, Cambridge, UK 
pATM(S1981) D25E5 13050 Cell Signaling TECHNOLOGY®, Danvers, MA,USA 
CDK1/CDC2 POH1 9116 Cell Signaling TECHNOLOGY®, Danvers, MA,USA 
pCDK1/CDC2(Y15) 10A11 4539 Cell Signaling TECHNOLOGY®, Danvers, MA,USA 
WEE1 D10D2 13084 Cell Signaling TECHNOLOGY®, Danvers, MA,USA 
pWEE1(S645) D47G5 4910 Cell Signaling TECHNOLOGY®, Danvers, MA,USA 
p-HISTONE H3(S10) 9701 Cell Signaling TECHNOLOGY®, Danvers, MA,USA 
CYCLIN B1 D5C10 12231 Cell Signaling TECHNOLOGY®, Danvers, MA,USA 
3.2.4 Immunofluorescence 
Immunofluorescence (IF) is used to visualize target molecules by labelling them with 
fluorescent dyes. Cells were seeded on sterilized glass coverslips in 24 well plates or 
in appropriate 8-well glass chamber slides (Nunc, Thermo Fisher Scientific). Cells 
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were then fixed with 4% paraformaldehyde for 20 min, permeabilized with PBS 1X 
with Triton X-100 at 0,5% for 10 min and saturated with PBS 1X with BSA 2% for 30 
min. Cells were then incubated with appropriated concentration of the primary 
antibody diluted in PBS 1X with 1X BSA for 1h at RT, washed three time with PBS 1X 
with BSA 1% to removed antibody excess and stained with the appropriate 
secondary antibody Alexa Fluor® (Invitrogen/Molecular Probes®) diluted in PBS 1X 
and BSA 1% for 1h at RT in the dark (for Alexa Fluor® 488 (green), 1:500 dilution, for 
Alexa Fluor® 546 (red), 1:1000 dilution). After washing three times with PBS 1X and 
BSA 1% coverslips were mounted on glass microscope slides with Prolong Gold 
Antifade with DAPI to stain nuclei (Thermo Fisher Scientific). IF were evaluated with 
a Nikon TE2000-S microscope with a 40X PlanFluor objective (Nikon). Images were 
acquired with ACT-1 software (Nikon). 
 
3.3 Cloning techniques 
3.3.1 Design and annealing of oligonucleotides 
The 3’ UTR of RAD17 cloning was performed according to protocol from pmirGLO 
Dual-Luciferase miRNA Target Expression Vector (Promega Corporation, Madison, 
USA) which allow the cloning of putative miRNA binding site of a gene into the 
vector. The sequence of the 3’UTR of RAD17 was obtained from UCSC Genome 
Browser (http://genome.ucsc.edu/index.html). Oligonucleotides pairs were 
synthesised by IDT (Integrated DNA Technologies, Coralville, Iowa, USA) in order to 
contain the desired miR-506 target region (seed sequence):  
forward: 5'-AAATAGCGGCCGCTACGAGTGTAAACTGTGTGCCTTATTTACT-3' 
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reverse: 5'-CTAGAGTAAATAAGGCACACAGTTTACACTCGTAGCGGCCGCTATTT-3' 
(the 3’UTR cloned in bold and the seed region in bold and underscored). 
Oligonucleotides were modified to include DraΙ and XbaΙ restriction sites at the 5’ 
and 3’end respectively of each oligonucleotide. Oligonucleotides were diluted to 1 
µg/µL in sterile water, and then 2 µL of each dilution were combined to 46 µL of 
Oligo Annealing Buffer (Promega Corporation, Madison, USA) following the 
manufacturer’s instruction. Annealing procedure was performed at 90°C for 3 min, 
then 37°C for 15 min following manufacturer’s instructions. 
 
3.3.2 Restriction digests of vector 
In order to obtain a pmirGLO vector with the overhangs complementary to the 
annealed oligonucleotide overhangs, 20 µg pmirGLO vector (Promega Corporation, 
Madison, USA) was digested in a two-step digestion overnight at 37°C in a 100 µL 
reaction containing 4 µL (80 units) of XbaI or DraI enzymes (New England Biolabs) 
and 10 µL of the appropriate buffers (buffer 2 and 4 respectively, New England 
Biolabs), with the remaining volume made up of DNA and nuclease-free water. BSA 
was required for DraI enzyme. Purification was performed with the Wizard® Plus 
Minipreps DNA Purification System kit (Promega Corporation, Madison, USA). To 
verify plasmid linearization and length 500 ng purified digested vectors were run on 
ethidium-bromide-stained 1% agarose gel electrophoresis alongside non-digested 
controls. Bands-signal was revealed using a Bio-Rad Gel Doc XR System (BIO-RAD, 
Hercules, CA, USA) and images were acquired using Quantity One® software. 
59 
 
3.3.3 Ligation of insert and vector 
Annealed oligonucleatides were diluted to a final concentration of 4 ng/μL and then 
8 ng were ligated to 100 ng of linearized vector in a 21 μL reaction containing 1 μL 
quick ligase (New England Biolabs), 10 μL of 2X quick ligase reaction buffer and 
DNA-free water to reach final volume. The ligation reaction was carried out by 
incubating samples RT for 5 min and immediately purified using the Wizard® Plus 
Minipreps DNA Purification System kit (Promega Corporation, Madison, USA). 
3.3.4 Transformation of competent E. coli cells and isolation of plasmid DNA 
To carry out transformation 50 μL electrocompetent E. coli TG1 cells were defrosted 
on ice prior to addition of 2 μL of purified ligation reaction. Cells were 
electroporated with MicroPulserTM electroporator (BIO-RAD, Hercules, CA, USA) 
then 10 μL or 100 μL of cells were spread onto a Petri dish of Tryptone Yeast-extract 
(TYE) broth medium [15 g bacteriological agar type A, 10 g tryptone USP, 5 g yeast 
extract (Diagnostic International Distribution SPA), 8 g NaCl: add ddH2O to 1 liter], 
containing 100 μg/ml of ampicillin sodium salt (Sigma-Aldrich, St. Louis, MO, USA) 
and glucose 1%, then incubated overnight at 37°C. Colonies were isolated and 
picked the following day to be screened by PCR to verify the presence of the insert. 
Screening PCR was carried out in 50 μL reactions with: 1 μL of forward and 1 μL of 
reverse primers (forward: 5’-TCCGCGAGATTCTCATTA-3’; reverse: 5’-
TCAGCTTCCTTTCGGGCT-3’) annealing on the vector at the sides of the insert, 10 μL 
of 5X Green GoTaq® Reaction Buffer, 2 μL of PCR nucleotide mix, 0.25 μL of Taq 
enzyme 5u/μL (GoTaq® G2, Promega Corporation, Madison, USA) and 35.75 μL of 
sterile water. PCR was carried out with an initial stage of 95°C for 10 min followed 
60 
 
by 35 cycles of 95°C for 1 min, 49°C for 1 min and 72°C for 10 min, with a final step 
of 72°C for 1 min. PCR products were run on a 3% agarose gel in order to verify the 
presence of the insert, then the correct orientation and sequence of the insert was 
verified by sequencing, using the above primers, performed by Eurofins Genomics-
genomic service (MWG Eurofins). The bacterial colony carrying the plasmid with the 
right insert was grown overnight at 37°C and 250 rpm in 60 ml of 2xTY medium 
[16gr tryptone USP, 10gr yeast extract (Diagnostic International Distribution SPA), 
5gr NaCl: add ddH2O to 1 liter], supplemented with 100 μg/ml of ampicillin sodium 
salt and glucose 1% to allow plasmid replication. The day after the recombinant 
plasmid was extracted from bacterial cell culture using QIAfilter Plasmid Midi Kit 
(QIAGEN), resuspended in Tris-EDTA buffer pH 8.0 and quantified with NanoDrop™ 
2000c (Thermo Fisher Scientific) and 500 ng were run on a 1% agarose gel to verify 
plasmid integrity. 
3.4 Molecular biology technique 
3.4.1 RNA extraction 
Total RNA was extracted with NucleoSpin® miRNA kit (Macherey-Nagel, GmbH & 
Co, Düren, Germany) following the manufacturer’s instruction. Briefly cells were 
harvested with trypsin and washed with PBS 1X, then centrifuged at 1500 rpm and 
stored as a pellet at -20°C until RNA extraction. At the moment of extraction, cell 
pellets were resuspended with 800 µL of TRIzol Reagent (Thermo Fisher Scientific), 
then 160 µL of chloroform were added and samples vortexed. Then samples were 
centrifuged at 12000 x g for 15 min at 4°C and aqueous phase recovered and loaded 
into columns. Samples were then washed with different buffers and RNA eluted in 
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30 µL of RNase-free water. RNA was then quantified using a spectrophotometer 
NanoDrop™ 2000c. 
3.4.2 Total RNA and microRNA reverse transcription 
RNA extracted from cells was reverse transcribed to cDNA to analyse genes and 
miRNAs expression via quantitative real time PCR.  
For total RNA reverse transcription 2 µg of total RNA were reverse transcribed to 
cDNA with High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems™, 
Foster City, CA, USA) using random hexamer primers following the manufacturer’s 
instruction. Reverse transcription of RNA was conducted in 100 μL reactions 
containing: 10X RT buffer (10 μL), 100 mM 25X dNTP Mix (4 μL), 50 μM Random 
Primers (10 μL), 0.5 U/μL RNAse inhibitor (0.8 μL), 50 U/μL multiscribe™ reverse 
transcriptase (5 μL), 100 ng/mL RNA (10 μL) and nuclease-free water (21 μL). Cycling 
conditions used were as follows: 25°C for 10 min, 37°C for 120 min, 85°C for 5 min. 
cDNA was stored at -20°C. 
For miRNA reverse transscription 10 ng of total RNA was reverse transcribed to 
cDNA with TaqMan® MicroRNA Reverse Transcription Kit (Applied Biosystems™, 
Foster City, CA, USA) using specific stem-loop reverse transcription primers 
following the manufacturer’s instruction. Reverse transcription of miRNA was 
conducted in 15 μL reactions containing: 100 mM dNTPs (0.15 μL), 10X RT buffer 
(1.5 μL), 20 U/μL RNase inhibitor (0.19 μL), 50 U/μL multiscribe reverse 
transcriptase (1 μL), nuclease-free water (4.16 μL), primer (3 μL), and 5 μL of total 
RNA diluted to 2 ng/μL. The cycling conditions used were as follows: 16°C for 30 
min, 42°C for 30 min, 85°C for 5 min. cDNA was stored at -20°C. 
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3.4.3 Quantitative Real time PCR (qRT-PCR) 
Real time PCR was used to quantify relative expression levels of genes or miRNAs of 
interest monitoring their amplification during the PCR in real time. I used TaqMan® 
assays based on TaqMan chemistry. The probe is labelled with a reporter 
fluorophore at the 5’ end and a non-fluorescent quencher at the 3’ end. When 
intact the quencher suppresses fluorescent emission by the reporter. In the 
presence of target sequence the probe anneals and is then cleaved upon 
amplification of the target sequence by the forward and reverse primers, contained 
in the TaqMan® assay. This produces separation of the quencher from the reporter 
and a fluorescent signal can be detected. Data is acquired whilst PCR is in the 
exponential phase and is measured when the reporter dye emission reaches a 
threshold, known as the cycle threshold (Ct). Results were normalised to 
housekeeping genes whose expression is known to remain stable, to correct for any 
errors in RNA content. Results are relative quantifications (RQ). The 2-∆∆Ct or the 2-∆Ct 
methods were used, when normalised to a reference gene or to the experimental 
control respectively, as specified for each experiment. qRT-PCR was performed 
using TaqMan® gene expression assays (Table 4) or TaqMan® MicroRNA Assays 
(Table 5). Twenty μL reactions were prepared for each sample containing: 2X 
TaqMan®Universal MasterMix II (10 μL), probe (1 μL), RNAse free water (8 μL) and 1 
μL cDNA. Samples were run in technical triplicates on a 96 well plate. qRT-PCR was 
run in a ABI Prism 7900HT sequence detection system (Applied Biosystems™ Foster 
City, CA, USA) using the following cycling conditions: 50°C for 20 sec, 95°C for 10 
min, 40 cycles of 95°C for 15 sec then 60°C for 60 sec. Glyceraldehyde 3-phosphate 
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dehydrogenase (GAPDH), and ribosomal protein L13A (RPL13A) were used as stably 
expressed housekeepers for gene expression, while RNU44 and RNU48 for miRNA 
expression. 
 
Table 4: List of the TaqMan® probes used 
Gene TaqMan Assay ID gene ID 
GAPDH Hs03929097_g1 2597 
RPL13A Hs01926559_g1 23521 
RAD17 Hs00607830_m1 5884 
RAD51 Hs00153418_m1 5888 
 
 
Table 5: List of the TaqMan® miRNA probes used 
miRNA TaqMan Assay ID MIRBASE ID 
RNU44 001094 
 
RNU48 001006 
 
hsa-miR-506-3p 001050 MIMAT0002878 
 
 
3.4.4 Luciferase assay 
Luciferase reporter assay is the most commonly used strategy to verify the direct 
interaction of a miRNA with a candidate target. It is based on the insertion of the 
miRNA target site (seed sequence) downstream of the Luciferase gene in a dual 
luciferase reporter vector, then the activities of the two luciferases are measured 
sequentially from a single sample. The wild-type miR-506 binding sites (portion 
including the seed sequence) of RAD17 were cloned downstream of Firefly 
luciferase gene in pmirGLO Dual-Luciferase miRNA Target Expression Vector 
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(Promega Corporation, Madison, WI). This vector contains Firefly luciferase (luc2) as 
primary reporter to monitor miRNA regulation and Renilla luciferase (hRluc-neo) as 
a control reporter for transfection normalization and selection. For the Dual-
Luciferase® Reporter Assay (Promega Corporation, Madison, WI), subconfluent 
HEK293T cells in 24-well plates were transfected with a triplicate repeat of pmirGLO 
reporter plasmid (0.5 μg) wild-type 3′-UTR construct alone or with miR-506 mimic 
or miR-ctrl (60 nM), and Lipofectamine® 2000 (1:1 ratio) (Invitrogen). Forty-eight 
hours after transfection, Dual-Luciferase® Reporter Assay was performed and Firefly 
and Renilla luciferase luminescence signals were determined following 
manufacturer’s instructions. Briefly cells were lysed with passive lysis buffer (PLB 
Buffer) and the culture plates rocked at RT for 15 min. Three μL of lysate were 
added to 100 μL of luciferase assay reagent (LARII) per tube and firefly 
measurement was performed using TD-20/20 luminometer (TURNER DESIGNS). 
Then 100 μL of Stop & Glo® reagent was added and the Renilla bioluminescence 
measured. Ratio of Firefly:Renilla was determined. 
3.5 Bioinformatic studies: miRNA Target prediction and identification of 
deregulated functions with Ingenuity Pathway Analysis 
 
Identification of miRNA binding sites within the 3’UTR of target genes (seed 
sequence), allows to obtain information on putative miR:mRNA interactions, thanks 
to the use of algorithms based on different factors for the more appropriate target 
prediction. Human miRNA target predictions were obtained from:  
 TargetScan 6.2 (http://www.targetscan.org/); 
 microRNA.org (http://www.microrna.org/microrna/home.do) database; 
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  Diana-microT-CDS (http://www.microrna.gr/microT-CDS.); 
  PITA (https://genie.weizmann.ac.il/pubs/mir07/mir07_prediction.html).  
In particular TargetScan6.2, version released in June 2012, focus on the prediction 
of protein coding gene to be a target of a miRNA if the 3’ UTR of the target harbours 
a conserved 7mer or 8mer motifs that can bind to the seed region. Diana-microT-
CDS and Pita, analogously to TargetScan, use the 5’ end of the miRNA to identify 
targets but with minor differences among length of the seed. Conservation across 
species and target sites free energy are considered. In order to identify commonly 
predicted mRNA targets, intersection of lists of mRNA targets, obtained from the 
different algorithms, was performed. I used VENNY 2.0 software, an interactive 
web-based tool that allow to compare up to four lists of elements and returns to 
the user Venn diagrams (http://bioinfogp.cnb.csic.es/tools/venny/index2.0.2.html). 
IPA (Ingenuity Pathway Analysis) is a powerful analysis tool that helps researchers in 
analyzing data in order to evaluate molecular and chemical interactions, cellular 
pathways and disease processes within a system. IPA returns to the user networks 
that help to understand how genes in a given dataset appear to work together at 
the molecular level. 
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3.6 Ovarian cancer patients selection 
3.6.1 INT-MI/CRO OC72 case material 
Seventy-two high-grade, advanced stage (III-IV) fresh frozen EOC samples collected 
at time of primary surgery were retrospectively selected from patients with optimal 
debulking (residual disease <1 cm) followed by standard chemotherapeutic 
treatment with platinum and taxanes. In detail, 20 patients underwent primary 
surgery at the Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan, Italy, 
while 52 patients at the IRCCS Centro Riferimento Oncologico (CRO) Aviano, Italy, 
after signing the informed consent. All samples were reviewed by a pathologist and 
only tumors with at least 70% of cellularity were included. All biological material 
was subjected to molecular analysis, gene expression and miRNA expression 
profiles by the Genomic Facility at INT and associated to complete clinical 
informations and follow up data.  
The time to recurrence after platinum treatment determines platinum sensitivity. 
EOC patients were defined as resistant, partially sensitive and sensitive if relapse 
occurred respectively within 6 months, between 6 and 12 months and after 12 
months from the end of first line platinum therapy. 
This current classification is based on the clinical observation that when patients 
who responded to first line treatment were re-treated with platinum analogs, the 
response was better the longer the interval from the last platinum dose was. This 
classification is now used as stratification criteria in clinical trials  
The complete data of the clinical case material are shown in Table 6. Samples were 
profiled for miRNA expression using Illumina v2 miRNA Chip (1145 miRNA assays) 
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and subsequently profiled for gene expression using Agilent SurePrint G3 Human 
gene expression 8x60K. 
 
Table 6: Clinical and pathological data of OC72 case material  
 
OC72 (n = 72) 
  N° % 
Age, years 
       median, range  54; 30-71 
Histology 
       Serous 53 74 
     Undifferentiated 8 11 
     Clear Cells 1 1 
     Endometroid 4 6 
     Others + Mixed 5 7 
     NA 1 1 
Stage (FIGO) 
  
     III 69 96 
     IV 3 4 
Grade 
  
     2 moderately differentiated 16 22 
     3, poorly differentiated 53 74 
     Undifferentiated 1 1 
     NA 2 3 
Amount of residual disease 
  
     NED 31 43 
     <1 cm, mRD 41 57 
Relapsing patients 
  
      R*<6 months      -refractory and resistant 20 28 
  6<R*<12 months   -partially sensitive 15 21 
     R*>12 months     - sensitive 37 51 
R*= relapse from the end of therapy; NED: non evident disease;  
mRD: minimal residual disease. 
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3.6.2 OC179 case material 
One hundred-seventy-nine (OC179) samples (chemo naive tumours obtained at 
primary surgery) from formalin-fixed paraffin embedded (FFPE) was retrospectively 
collected from Multicentre Italian Trial in Ovarian cancer clinical trial 2 (MITO2)158. 
All samples were reviewed by a pathologist and only tumors with at least 70% of 
cellularity were included. RNA was extracted at INT-Pascale Naples for miRNA 
expression profile and for forty-four samples (OC44) out of 179 RNA aliquots were 
available for qRT-PCR miRNA expression validation. Clinical and pathological 
characteristics of OC44 are listed in Table 7. 
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Table 7: Clinical and Pathologic characteristics of OC44 case material 
 
OC179 (n = 44) 
  N° % 
Age, years 
       median, range  58; 38-74 
Histology 
       Serous 36 82 
     Undifferentiated 1 2 
     Clear Cells 1 2 
     Endometroid 4 9 
     Others + Mixed 2 5 
Stage (FIGO) 
  
     IIc 1 2 
     III 34 77 
     IV 9 20 
Grade 
  
     1 well differentiated 1 2 
     2 moderately differentiated 3 7 
     3, poorly differentiated 37 84 
     Undifferentiated 1 2 
     NA 2 5 
Treatment 
  
     Carboplatin + Paclitaxel 23 52 
     Carboplatin + PLD 21 48 
Amount of residual disease 
  
     NED 8 18 
     <1 cm 7 16 
     >1 cm 28 64 
PLD: Pegylated Liposomal Doxorubicin; NED: non evident disease.  
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3.7 Statistical analysis 
Statistical analyses were performed using GraphPad Prism 5 and 6 (GraphPad 
Software). This software was used to make graphs after analysis. Statistical 
significance of differences was determined using one-way ANOVA, two-way ANOVA 
or two-tailed Student’s t-test as specified for each analysis. Significance was 
indicated as * when p<0.05; ** when p<0.01; *** when p<0.001. 
Quantification of western blot bands was performed by Quantity One software. 
KM-plotter (http://kmplot.com/analysis/) and OvMark 
(http://glados.ucd.ie/OvMark/index.html) online tools were used to assess the 
effect of the RAD17 on ovarian cancer prognosis. 
CompuSyn software (CompuSyn, Inc), based on the Chou-Talalay's CI method for 
determining synergism or antagonism automatically, was used to calculate 
combination index (CI) in drug combination experiments.  
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4 Results 
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AIM 1: Investigating the potential role of miR-506 in the response to 
chemotherapeutic treatments and identifying possible miR-506 targeted genes 
involved in chemo-response 
4.1 Clinical impact of miR-506 expression in EOC patients  
My research group previously published that the down-modulation of ChrXq27.3 
miRNA cluster (miR-506 family) was independently associated with early relapse in 
advanced stage EOC patients and that miR-506 ectopic expression in EOC cells 
increased their sensitivity to chemotherapeutic agents144. Taking advantage of the 
miRNA expression profiles analyses performed by my research group on 
independent EOC case materials, I explored the possible association between miR-
506 expression levels and response to platinum-based therapy. As shown in Figure 
11 panel A, high miR-506 expression in OC72 case material was significantly 
associated with platinum sensitivity supporting the data observed in vitro following 
its transfection in EOC cells144. As shown in Figure 11 panel B I have been able to 
validate, by real time quantitative PCR (qRT-PCR), the clinical association of miR-506 
expression with platinum sensitivity in further 44 EOC samples derived from a case 
material associated to the MITO2 clinical trial143, 158, 159. 
These observations led me to hypothesize for miR-506 a key role in EOC response to 
drug treatment and I therefore search for the appropriated cellular models for 
further biological assays. 
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Figure 11: Expression of miR-506 correlates with EOC patients’ platinum sensitivity  
A) MiR-506 expression assessed by microarray analysis in OC72 case material. MiR-506 Log2 
expression intensity plotted B) qRT-PCR validation of miR-506 expression in 44 
retrospectively collected EOC patients from the MITO2 clinical trial. RNU48 and RNU44 
were used for normalization in qRT-PCR experiment. -ΔCt values plotted. Patient 
s were categorized in both datasets for response to platinum treatment as: resistant (PFS < 
6 months), partially sensitive (PFS from 6 to 12 months), sensitive (PFS > 12 months). P 
value from one-way analysis of variance with Tukey’s multiple comparison as post-test (** 
p<0.01; ***p<0.001).  
 
 
4.2 MiR-506 is expressed at low level in EOC cell lines 
In order to identify EOC models with different expression levels of miR-506 to be 
used for gain or loss of function experiments, I screened for miR-506 expression 
level a panel of EOC cell lines available at my laboratory by qRT-PCR analysis. As 
internal controls I used RNA samples obtained from EOC patients included in 
previous study of my research group144 and known to have high (1H, 2H) or low (3L, 
4L) miR-506 expression. As shown in Figure 12 (left panel) all EOC cell lines 
displayed lower expression level of miR-506 compared to positive controls 1H and 
2H. To make sure that the downregulation of miR-506 in EOC cell models was not a 
phenomenon related to the ovarian cancer histotype, I extended the analysis to a 
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number of cancer cell lines of different histotypes: epidermoid carcinoma (A431), 
large cell lung cancer (H460), prostate cancer (PC3, DUI45, LNCAP), breast 
carcinoma (MDA-MB-468, MCF-10) and colon cancer (HCT). Similarly to what 
observed in EOC cell lines, qRT-PCR analysis showed again very low expression 
levels of miR-506 compared to positive controls (Figure 12, right panel). These 
results are in line with data from other publications reporting miR-506 low 
expression levels in cancer cell lines160-162. These observations led me therefore to 
use my in vitro EOC models essentially for gain of function experiments aimed to 
achieve higher expression of miR-506. The p53 null platinum resistant SKOV3 and 
the p53wt platinum sensitive OAW42 cell lines were selected for the majority of 
further biological assays. 
 
Figure 12: MiR-506 expression level in cancer cell lines 
MiR-506 was tested in a panel of EOC cell lines (left panel), as well as in a panel of cancer 
cell lines other than ovary (right panel), using qRT-PCR method. RNU48 and RNU44 were 
used for normalization. Values are expressed as relative quantification value (RQ, 2-ΔΔCt). 
Expression levels of miR-506 were compared to those of positives (1H and 2H) and 
negatives (3L and 4L) controls from patients analysed for miRNA expression level and 
identified as miR-506 high- or low-expressing patients in previous study of my research 
group144 . Data are mean ± SD. 
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4.3 MiRNAs transient transfection is a suitable method for long-term biological 
evaluations 
To perform gain of function experiments I transiently transfected miR-506 or 
scrambled miRNAs in my in vitro EOC cellular models. In order to assess the extent 
of miRNA expression over time, following transient transfection, SKOV3 cell line was 
evaluated by qRT-PCR for expression of transfected miRNAs at different time points. 
I obtained a consistent induction of miR-506 expression 48 hours after transfection 
(Figure 13), in accordance with the transfection protocol which indicates this time 
point as the best in order to observe maximal transfection efficiency. Moreover, I 
was able to observe that the high expression of miR-506 remained essentially 
unchanged up to 96 hours after transfection (Figure 13). These results indicate that 
miR-506 expression upon transient transfection is persistent enough to observe 
biological changes over time, and support the efficacy of this protocol for 
experiments requiring long observation time such as clonogenic survival assay used 
to test cell sensitivity to drug treatments.  
Figure 13: Expression of miR-506 is maintained over time  
qRT-PCR experiment reporting that miR-506 expression is stable, with no substantial 
changes, for up to 96h following miR-506 mimic transfection. RNU48 and RNU44 were used 
for normalization. Values are relative quantifications (RQ, 2-ΔΔCt). scr: scramble miR; 506: 
miR-506 mimic. Data are mean ± SD of a representative experiment out of two performed. 
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4.4 MiR-506 overexpression enhances sensitivity to platinum  
Upon miR-506 overexpression, we previously described an increased response to 
platinum (DDP) treatment in the p53wt DDP sensitive OAW42 cell line144. In order to 
check miR-506 contribution in response to platinum treatment also in resistant EOC 
cells, I transiently transfected miR-506 mimic or scramble control miR in the EOC 
cell lines SKOV3 and A2774, carrying null and mutated p53 respectively. The day 
after transfection I exposed cells to serial dilution of DDP (from 0.1 to 100 µM) and 
percentage of growth was assessed 72 hours later. MiR-506 transfection efficiency 
was evaluated 48h after transfection by qRT-PCR in both cell lines (Figure 14D). 
MiR-506 expression was able to significantly re-sensitise A2774 cell line with a drop 
of IC50 of 3 fold as compared to scr control (Figure 14A, left panel), while no 
induced sensitivity to DDP was observed in SKOV3 cell line (Figure 14A, right panel). 
Since miR-506 reintroduction was not able to induce a DDP sensitisation in the 
SKOV3 resistant cell model, I then performed on this cell line a clonogenic assay as 
alternative approach to assess response to DDP at longer time points adjusting drug 
concentration according to literature data. MiR-506 and scr transfected SKOV3 cells 
seeded in six-well plates, were exposed to different doses of DDP ranging from 0.3 
to 1 µM and the ability of a single cell to grow into a colony was evaluated after 10-
14 days. In this experimental conditions, miR-506 forced expression significantly 
enhanced SKOV3 cells sensitivity to DDP treatment compared with control cells 
(Figure 14B). As expected similar results of increased sensitisation to DDP treatment 
following miR-506 forced expression was observed in the sensitive OAW42 cell line 
(Figure 14C). MiR-506 transfection efficiency was evaluated 48h after transfection 
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by qRT-PCR (Figure 14D). Taking into account that SKOV3 is considered a particular 
resistant cell line, these results further highlights the role of miR-506 as chemo-
sensitising miRNA.  
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Figure 14: Forced expression of miR-506 increased platinum sensitivity in EOC cell lines 
A) A2774 and SKOV3 cell lines were transfected with miR-506 (506) and scramble control 
(scr), seeded in 96 well plates, treated with DDP at at the indicated μM concentrations and 
evaluated by CellTiter-Glo® assay 72h after DDP treatment. B) and C) Clonogenic assay on 
SKOV3 (B) and OAW42 (C) cell lines. Percentage of relative colony formation rate of miR-
506 vs scr transfected cells (left panels). Clonogenic assay performed in SKOV3 and OAW42 
cell lines (right panels) treated or not (NT) with DDP at the indicated μM concentrations. 
For each experimental condition a representative well of three independent experiments, 
each one performed in triplicates, is reported. Colonies were counted using optical 
microscope. D) qRT-PCR experiments performed 48h following miR-506 mimic transfection 
in order to evaluate miR-506 transfection efficiency. RNU48 and RNU44 were used for 
normalization. Values are relative quantifications (RQ, 2-ΔΔCt). scr: scramble miR; 506: miR-
506 mimic. Data are mean ± SD of at least three experiments. Two way ANOVA and 
Bonferroni’s post test was used to compare miR-506 transfected cells vs scr transfected 
cells (*p<0.05; ** p<0.01; ***p<0.001). 
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4.5 Identification of miR-506 target genes and functional analysis of miRNAs 
targets by Ingenuity Pathway analysis (IPA) 
In order to identify the molecular mechanisms by which miR-506 sensitise EOC cells 
to platinum treatments, I looked at genes potentially targeted by miR-506. I took 
advantage of the use of publicly available software programs such as TargetScan6.2, 
Diana-microT, PITA, based on different algorithms/computational methods which 
apply as determinants: perfect base pairing with the miRNA seed region (the 2-7 
nucleotides on the 5’ end of a miRNA), accessibility of binding sites, thermodynamic 
stability of binding sites, target-site abundance, evolutionary conservation of the 
seed and binding position in the 3’ UTR. Since none of the software used consider 
all the aspects of miRNA-mRNA interactions I intersected the target lists obtained 
from the different prediction algorithms using VENNY 2.0 software. As reported in 
the Venn diagram in Figure 15A, around 500 entries were found to be common 
genes in the three data sets and therefore considered as reliable targets to be 
validated. Among top score predicted genes I identified: RAD17 and RAD51 both 
related to DNA repair, CHK1, WEE1 and CHK2 related to cell cycle and CDH2, VIM, 
SNAI2 and VCAN related to epithelial mesenchymal transition (EMT) and 
extracellular matrix. 
The list of common predicted genes targeted by miR-506 was challenged with IPA 
tool, which help to understand how genes in a given dataset appear to work 
together at the molecular level. Deregulated pathways were derived with top score 
functions listed in Figure 15B. The most significant molecular networks (pathway’s 
score>20), were associated with DNA replication, recombination and repair, cell 
cycle and cellular assembly and organization, related to EMT process. These results 
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are consistent with the role of miR-506 both in the regulation of genes involved in 
alteration of the normal organization of the extracellular matrix and with EMT and 
in the process of DNA damage repair (DDR). 
 
 
 
Figure 15: Identification of miR-506 target genes and related deregulated cell functions  
A) Venn diagram of the target genes of miR-506 predicted by the three algorithms Diana, 
Pita and TargetScan. B) The first 5 networks identified by IPA on the bases of the 500 
commonly predicted mi-506 target genes, with their p-score are shown. The score takes 
into account the number of genes in the network and the size of the network to 
approximate how relevant this network is to the original list of genes and allows the 
networks to be prioritized for further studies.  
  
Among  the common predicted target genes 
with the highest score we identified: 
RAD51, RAD17, CHEK1, CHEK2, WEE1 (DNA 
Damage Response (DDR) pathway)
CDH2, VIM, SNAI2, VCAN  (related to EMT)
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B
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4.6 RAD51 and RAD17 are regulated by miR-506 
To decipher the role of miR-506 in modulating EOC sensitivity to drug treatment, 
among genes found to be potentially targets of miR-506, I focused on RAD51 and 
RAD17 genes, both involved in DNA damage repair pathway. Acting as damage 
sensors (RAD17) or damage signal mediators (RAD51), these genes are important 
for the recruitment of BRCA1 and BRCA2 to the DNA damage sites activating repair 
processes. In this perspective, EOC is an intriguing challenge, indeed it has been 
shown that in these tumours both germline and somatic mutational inactivation of 
genes related to DNA repair pathway (i.e. BRCA1 and BRCA2) is associated with a 
more favorable outcome, causing sensitisation to DNA damaging drugs 34, 35. I 
hypothesized that if miR-506 consistently regulates the above mentioned genes 
related to DNA repair, its expression could confer a BRCAness phenotype 
characterised by increased platinum sensitivity without BRCA1/2 mutations and 
might contribute in determining the overall cell sensitivity to DNA damaging agents. 
To determine whether miR-506 modulation could affect RAD51 and RAD17 
expression in my in vitro models I ectopically expressed miR-506 in a panel of EOC 
cell lines: SKOV3, OAW42, A2774 and IGROV1. I performed western blot analysis 
48/72 hours after transfection and I was able to detect an evident reduction of both 
RAD51 and RAD17 protein expression levels, compared to scramble transfected 
control cells (Figure 16A). MiR-506 overexpression significantly decreased also 
RAD51 and RAD17 mRNA levels as confirmed by qRT-PCR (Figure 16B). The miR-
506-RAD51 axis was investigated in the framework of a collaborative study between 
my group and Dr Wei Zhang at the MD Anderson Cancer Center147. However, RAD17 
82 
 
involvement in EOC biology has never been investigated and it could possibly give 
new insights about mechanisms of drug resistance. I therefore decided to focus my 
attention on miR-506 direct modulation on RAD17 and performed functional 
analysis to better characterize its role in EOC progression. 
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Figure 16: miR-506 regulates expression of RAD17 and RAD51  
Four EOC cell lines (OAW42, IGROV1, SKOV3, A2774) were transfected with miR-506 mimic 
(506) or scr-miR (scr). Proteins and mRNA levels were evaluated at 48 hours after 
transfection. A) Western blot analysis was carried out in order to check RAD17 and RAD51 
protein levels. β-actin was used as loading control. Quantification of protein expression by 
QuantityOne software was performed and bar chart representing protein expression fold 
change of miR-506 transfected cells versus controls for both RAD17 and RAD51 is reported 
below each western blot panel. A representative experiment out of three performed is 
shown. B) qRT-PCR analysis of RAD17 (left panel) and RAD51 (right panel) mRNA expression 
levels in the same EOC cell lines. GAPDH was used for normalization. Values are percentage 
of down-regulation of RAD17 and RAD51 in miR-506 reconstituted cells versus scr 
transfected cells. Data are mean ± SD of at least three experiments. 
 
OAW42
scr          506
RAD51
RAD17
Actin-β
scr           506
IGROV1 SKOV3
scr          506scr          506
A2774
A
B
A 2 7 7 4
0 . 0
0 . 2
0 . 4
0 . 6
0 . 8
1 . 0
  R A D 1 7             R A D 5 1
p
r
o
t
e
i
n
 
e
x
p
r
e
s
s
i
o
n
 
f
o
l
d
 
c
h
a
n
g
e
 
v
s
 
c
o
n
t
r
o
l
S K O V 3
0 . 0
0 . 2
0 . 4
0 . 6
0 . 8
1 . 0
  R A D 1 7             R A D 5 1
p
r
o
t
e
i
n
 
e
x
p
r
e
s
s
i
o
n
 
f
o
l
d
 
c
h
a
n
g
e
 
v
s
 
c
o
n
t
r
o
lI G R O V 1
0 . 0
0 . 2
0 . 4
0 . 6
0 . 8
1 . 0
  R A D 1 7             R A D 5 1
p
r
o
t
e
i
n
 
e
x
p
r
e
s
s
i
o
n
 
f
o
l
d
 
c
h
a
n
g
e
 
v
s
 
c
o
n
t
r
o
lO A W 4 2
0 . 0
0 . 2
0 . 4
0 . 6
0 . 8
1 . 0
  R A D 1 7             R A D 5 1
p
r
o
t
e
i
n
 
e
x
p
r
e
s
s
i
o
n
 
f
o
l
d
 
c
h
a
n
g
e
 
v
s
 
c
o
n
t
r
o
l
5 0 6
s c r
0
50
100
150 SCR
506
OAW42    IGROV     SKOV3     A2774
R
A
D
1
7
 m
R
N
A
 (
%
 v
s
 s
c
r)
0
50
100
150 SCR
506
OAW42    IGROV     SKOV3     A2774
R
A
D
5
1
 m
R
N
A
 (
%
 v
s
 s
c
r)
84 
 
4.7 RAD17 is a direct target of miR-506  
The RAD17 mRNA contains one miR-506 binding site in its 3'UTR as detected by 
different prediction algorithms (Figure 17, upper panels). I therefore hypothesized 
that RAD17 was regulated by miR-506 through direct targeting to its 3’UTR. To test 
this hypothesis, I performed a Dual-Luciferase® Reporter assay. A 40 base pair 
region of the RAD17-3’UTR containing the miR-506 seed sequence was firstly cloned 
into the pmirGLO vector downstream of Firefly luciferase gene, under the control of 
the human phosphoglycerate kinase (PGK) promoter and the sequence of the insert 
was confirmed by sequencing. HEK293T cells were co-transfected with pmirGLO 
empty vector, as control, and with pmirGLO vector containing the miR-506 seed 
region alone or in combination with miR-506 or scr-miR.  
Dual Luciferase activity was assayed 24 hours post transfection and Firefly luciferase 
activity normalized (firefly luciferase activity/Renilla luciferase activity). Expression 
of miR-506 significantly reduced the normalized luciferase activity in HEK293T cells 
compared to the empty vector transfected control cells (Figure 17, lower panel). To 
confirm that miR-506 specifically regulated this gene, I transfected cells also with 
another miRNA (miR-unrelated) whose sequence does not have complementary 
seed in the 3’ UTR of RAD17. I observed a luciferase activity comparable to the scr 
transfected cells and significantly higher than the luciferase activity detected in miR-
506 transfected cells (Figure 17 lower panel). Overall these results demonstrate that 
the overexpression of miR-506 causes a decrease in RAD17 mRNA and protein 
expression through direct binding on the RAD17 3'UTR.  
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Figure 17: RAD17 is a direct target of miR-506 
Images from microRNA.org and TargetScan prediction tools showing the alignment of miR-
506 within the predicted binding site in the RAD17 3’UTR (upper panels). Dual-Luciferase® 
Reporter assay confirming RAD17 as a direct target of miR-506 (lower panel). HEK293T cells 
were transfected with pmiRGLO empty vector (pmiRGLO, white bar), or pmiRGLO 
containing the putative binding site of miR-506 in the RAD17 3’UTR in combination with a 
scrambled miRNA (scr) (pmiRGLO+miR-scr, black bar), miR-506 (pmiRGLO+miR-506, gray 
bar) and an unrelated miRNA (pmiRGLO+miR-unrelated, dotted bar). Results are 
percentage of Relative Luminometer Units (RLU) of the ratio Firefly/Renilla. Data are mean 
± SD of at least three experiments. Student’s t-test was used to compare miR-506 
transfected cells versus scr transfected cells (** p<0.01). 
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4.8 Clinical relevance of RAD17 in EOC patients 
In order to confirm my in vitro data on the correlation between RAD17 and miR-
506, I analysed their expression on EOC patients from OC72 case material for whom 
both miRNA and mRNA profiles were available. As reported in Figure 18A, RAD17 
expression was significantly anti-correlated with miR-506 expression (p=0.039) 
further supporting the importance of this direct regulation. With the aim to 
correlate RAD17 gene expression levels with patients’ clinical outcome I 
interrogated the online tool OvMark, that integrate gene expression profiles data 
from up to 2129 EOC samples (around 17000 genes; 14 datasets), and in particular I 
selected patients for whom information about a platinum therapy was annotated. 
The RAD17 high expression levels identified patients with worse prognosis; Figure 
18B left panel reports the Kaplan-Meier (KM) curves for Disease Free survival (DFS), 
HR= 1.48, 95% CI=1.22–1.79, log‐rank P=0.000053; Figure 18B right panel reports 
KM curves for overall survival (OS), HR=1.61, 95% CI=1.26–2.05, log‐rank 
P=0.000092, using median cut off to determine high and low expressing patients. 
These results suggest a prognostic role for RAD17 expression. Concordantly, high 
expression of miR-506 has been associated with a favorable prognosis147. 
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Figure 18: RAD17 is anticorrelated with miR-506 and associates with poor prognosis in 
EOC samples 
A) RAD17 expression by gene expression analysis in EOC patients from OC72 case material. 
RAD17 expression resulted to be anti-correlated with miR-506 expression. Data are log2 
RAD17 expression intensity. Student’s t-test was used to compare miR-506 high expressor 
patients versus miR-506 low expressor patients (* p=0.039).  
B) Prognostic significance of RAD17 expression levels evaluated with the online tool 
OvMark (http://glados.ucd.ie/OvMark/index.html) generating DFS (left panel) and OS (right 
panel) curves in patients for whom information about platinum treatment was specified in 
the datasets (GSE30161, GSE9899 and GSE32062). KM curves were generated using a 
median cut off. Black and Grey lines indicate OC patients with high and low RAD17 
expression, respectively. The total number (n) of patients in the two categories is shown. 
Hazard ratios (HR) with CI (confidence interval) and p values (log rank p, for evaluation of 
significance) are shown at the top of each panel.  
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4.9 RAD17 silencing sensitises EOC cells to platinum  
According to its role in DDR acting as a sensor of DNA damage, I hypothesized that 
RAD17 activity could be involved in response to DNA damaging drugs. In order to 
evaluate whether RAD17 reduction could be critical for platinum sensitivity in EOC 
cells, I performed CellTiter-Glo® assays in SKOV3 and OAW42 EOC cell lines. Specific 
inhibition of RAD17 gene expression was obtained by RNA interference method. In 
particular I transiently transfected cells with a pool of 4 siRNAs against RAD17 
(siRAD17) or with a siRNA control sequence (siCTRL). Silencing efficacy was 
evaluated 72 hours after transfection at protein level, obtaining an almost totally 
reduction of protein expression in both cell lines as compared to their controls 
(Figure 19A-B). RAD17 silenced SKOV3 cells resulted more sensitive to platinum 
treatment across the dose range as compared to siCTRL transfected cells with a 
drop in the IC50 of 3 fold (Figure 19C). A significant effect of sensitisation upon 
platinum treatment was observed also in the OAW42 cell line with a drop in the 
IC50 of 2.5 fold (Figure 19D). Effect of RAD17 silencing in inducing sensitisation to 
DDP treatment was similar to miR-506 reconstitution effect as shown previously in 
Figure 14B and 14C. Overall these data are suggestive of the important role of 
RAD17 expression in modulating platinum sensitivity in EOC cell lines. 
 
89 
 
 
Figure 19 Effect of RAD17 silencing on sensitivity to platinum  
SKOV3 and OAW42 cell lines were transfected with RAD17 (siRAD17) and ctrl (siCTRL) 
siRNAs and seeded in 96 well plates for CellTiter-Glo® assays. The day after transfection 
cells were treated with serial dilution of DDP as indicated in the graphs. A-B) Western blot 
analysis of RAD17 silencing efficacy in SKOV3 and OAW42 cell lines. C) SKOV3 and D) 
OAW42 cell lines treated with DDP. Percentage of viability of siRAD17 and siCTRL 
transfected SKOV3 (C) and OAW42 (D) cells was evaluated by CellTiter-Glo® assay 72h after 
DDP treatments. Data are mean ± SD of at least three experiments. Two way ANOVA and 
Bonferroni’s post test was used to compare siRAD17 transfected cells versus siCTRL 
transfected cells (*p<0.05; ** p<0.01; ***p<0.001). 
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4.10 RAD17 is directly involved in miR-506-induced drug sensitisation 
To verify that RAD17 is a key factor in determining sensitisation induced by miR-506 
expression, I employed single-stranded modified RNAs, named target protectors 
(TP) that are designed to specifically interfere with the interaction of a given miRNA 
with its specific target gene (Figure 20A). By complementary binding to the seed 
sequence in the 3’UTR of the targeted gene, TP compete with the miRNA for 
binding to the target and block miRNA-mediated repression of a specific mRNA 
without affecting other targets. To this aim I co-transfected miR-506 reconstituted 
SKOV3 cells with or without two different concentrations (40 nM and 60 nM) of a TP 
designed to be fully complementary to miR-506 binding site within the RAD17 
3’UTR (RAD17-TP), thus preventing the interaction of miR-506 with RAD17 mRNA. I 
found that RAD17-TP was able to significantly recover RAD17 expression at both 
mRNA and protein level in miR-506 reconstituted SKOV3 cells compared to miR-scr 
transfected cells in a dose dependent way (Figure 20B and 20C, respectively). As 
shown in Figure 20C, RAD51 protein downregulation mediated by miR-506 was not 
affected by RAD17-TP, further supporting the specificity of the system. The same 
transfected cells were plated to perform a clonogenic assay following platinum 
treatment. Interestingly the co-transfection with TP-RAD17 was able to almost 
completely abrogate the platinum-sensitisation effect induced by miR-506 
reconstitution in a dose dependent way (Figure 20D). These results indicate that 
despite the large number of miR-506 targets, the rescue in sensitisation to platinum 
treatment is at least in part a result of RAD17 regulation by miR-506 thus confirming 
a central role of this direct regulation in chemoresponse. 
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Figure 20: RAD17 contributes to mediate miR-506 induced chemosensitisation 
A) Mechanism of action of miScript target-protector (TP) adapted from Zhang et al163. 
SKOV3 cells were transfected with miR-506 (506) or scramble (scr) in presence or absence 
of RAD17 target protector (RAD17-TP) at two different concentrations. B) qRT-PCR showing 
RAD17 expression level reconstitution after RAD17-TP co-transfection in miR-506 or scr 
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transfected cells. GAPDH and RPL13A were used for normalization C) Western blot analysis 
showing RAD17 protein level after RAD17-TP co-transfection. RAD51 protein expression 
level was used as positive control of miR-506 efficacy (left panel). Relative protein 
quantification of RAD17 normalized against vinculin (VINC) performed by Quantity One 
software and represented as ratio of RAD17 band intensity of miR-506 vs scr for each 
couple. VINC was used as loading control (right panel). D) Percentage of relative colony 
formation rate following treatment with platinum (DDP) at indicated doses of miR-506/scr 
SKOV3 reconstituted cells alone or co-transfected with RAD17-TP (two different doses, 40 
nM dashed lines, 60 nM dotted lines). Data are mean ± SD of at least three experiments. 
Two way ANOVA and Bonferroni’s post test was used to compare miR-506 transfected cells 
versus miR-506+RAD17-TP 60 nM transfected cells (** p<0.01; ***p<0.001). 
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AIM 2: Define the miR-506-driven molecular mechanisms at the basis of chemo-
response. 
4.11 Effect of miR-506-RAD17 regulatory axis on sensitivity to PARP inhibitors 
I showed that miR-506 reintroduction was able to sensitise EOC cells to platinum 
treatment. Since cells with defects in DNA repair pathway has been shown to be 
sensitive to DNA-damaging drugs and to PARP inhibitors164, and since miR-506 
targets and regulates important components of the DNA damage response (such as 
RAD17 and RAD51), I hypothesized that this miRNA could modulate also response 
to PARP inhibitors. I therefore tested my hypothesis on EOC cells treating them with 
olaparib, a commercially available PARP inhibitor. To this end I selected the p53null 
SKOV3 and the p53wt OAW42 cell lines and transfected them with miR-506 mimic 
or a scramble control miR. Cells were seeded in 6 well plates in order to perform a 
clonogenic assay. The day after cells were exposed to different doses of olaparib 
ranging from 1 to 10 µM and the ability of a single cell to grow into a colony was 
evaluated after 10-14 days. MiR-506 forced expression significantly enhanced 
SKOV3 and OAW42 cells sensitivity to olaparib treatment as compared with control 
cells (Figure 21A) with drop in the IC50 of 2 fold for both cell lines. Importantly, I 
obtained the same sensitisation to PARP inhibitor olaparib in both cell lines when I 
performed a phecocopy experiment by silencing of RAD17 expression with siRNAs, 
as shown in Figure 21B with drop in the IC50 of 2 fold for SKOV3 and 1.5 fold for 
OAW42. These results further suggest that miR-506 induced olaparib sensitisation is 
also a result of RAD17 direct targeting and are supportive of the importance of this 
new regulatory axis in interfering with DNA repair machinery thus modulating drug 
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response. Furthermore they suggest the possible use of miR-506 expression level to 
assess EOC BRCAness phenotype and therefore sensitivity to PARP inhibitors. 
 
Figure 21: Forced expression of miR-506 induce sensitivity to PARP inhibitors and the 
effect is phenocopied by RAD17 silencing 
SKOV3 and OAW42 cell lines were transfected with miR-506 (506) and control scramble-
miR (scr) or silenced with siRNA against RAD17 (siRAD17) or with a control siRNA (siCTRL) 
and seeded in 6 well plates for clonogenic assays. Percentage of relative colony formation 
rate of A) miR-506 versus scr transfected cells and of B) siRAD17 versus siCTRL transfected 
cells are reported. Colonies were counted using optical microscope. Data are mean ± SD of 
at least three experiments. Two way ANOVA and Bonferroni’s post test was used to 
compare miR-506 transfected cells versus scr transfected cells (*p<0.05; ** p<0.01; 
***p<0.001).  
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4.12 MiR-506 increases frequency of chromosomes breaks and causes 
abnormalities in mitotic progression in platinum treated cells 
It has been recently reported that RAD17 deletion trigger genomic instability and 
led to DNA fragmentation and mitotic catastrophe in gemcitabine-treated 
pancreatic cancer cells80, 165. I tested whether miR-506 reintroduction could be 
responsible of such instability, mimicking the effects of RAD17 depletion. To this 
purpose I selected SKOV3 cells as most representative of the majority of EOC and I 
transfected cells with miR-506 mimic or scr and, 48 hours after DDP treatment, I 
performed an immunofluorescence analysis to evaluate its role in inducing mitotic 
defects. Immunostaining of acetylated alpha-tubulin to visualize the mitotic spindle, 
phosphorylated histone H3 (ser10) as marker of mitotic cells, and DAPI to 
counterstained nuclei, revealed in miR-506 reconstituted cells the presence of 
aberrant mitotic figures, such as monopolar and multipolar spindles or lagging 
chromosomes, resulting from asynchronous chromosomes movements at mitosis 
anaphase (Figure 22B, 22C, 22D), while normal mitosis were observed in scr control 
transfected cells (Figure 22A). Moreover, I assessed the effect of miR-506 on the 
appearance of micronuclei, small extra-nuclear chromatin-containing bodies which 
result from unrepaired chromosome breaks or lagging chromosomes. In response to 
DDP treatment, miR-506 reconstituted SKOV3 cells displayed higher number of 
micronuclei compared to scr control cells (Figure 22E), which reflected elevated 
genomic instability of platinum treated cells induced by miR-506 transfection. 
Overall these results suggest that sensitisation to drug treatments induced by miR-
506 reintroduction may be also a consequence of failure of cell division processes.  
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Figure22: MiR-506 reintroduction causes abnormal mitotic figures following drug 
treatment 
MiR-506 reconstituted SKOV3 cells were treated with 3 µM of DDP. 48 h after transfection 
cells were fixed and immunofluorescence analysis was carried out for Acetylated alpha-
tubulin (α-tubulin-ac, green), phosphorylated histone H3 (pH3, red) and DAPI (nuclei, blue). 
A) Normal mitosis occurring in scr cells, B) monopolar mitosis, C) multipolar mitosis, D) 
lagging chromosomes. E) Micronuclei in miR-506 transfected cells and scr control. 
Magnification 40X. 
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4.13 MiR-506 impacts on DNA Damage 
Given the effects of miR-506 reconstitution in inducing aberrant mitotic figures 
upon DDP treatment, together with the evidence that miR-506 directly targets and 
regulates different molecules involved in DDR, I further investigated the impact of 
miR-506 reintroduction on DNA damage. To this end I analysed the expression level 
of γH2AX (phosphorylated in serine 139), a recognized marker of DNA DSBs. SKOV3 
cells were transfected with miR-506 and scr control. The day after, cells were 
treated with DDP at the concentration of 3 µM for 24 hours to induce DNA damage 
and western blot analysis was performed. I observed a decrease in γH2AX 
expression level in miR-506 treated cells compared to scr control treated cells 
(Figure 23A). I also performed immunofluorescence analysis in order to visualize 
γH2AX localization at DSBs sites upon platinum treatment. Figure 23B shows a 
reduced number of γH2AX positive cells, containing more than 15 foci, in miR-506 
reconstituted cells, with a mean percentage reduction of 30% in miR-506 
transfected cells compared to scr control cells (Figure 23C). Similar to miR-506 
reconstitution effects, RAD17 silencing was responsible of the reduction of γH2AX 
expression level in DDP treated cells, (Figure 23D). These results suggest that miR-
506 reduces γH2AX recruitment at DSBs sites thus impairing DNA damage response.  
RAD17 is a DNA damage sensor protein important for ATR checkpoint signalling in 
response to DNA damage insults, such as platinum treatments. It has been recently 
shown that RAD17 play a role also in the early recruitment and maintenance at 
damage sites of the MRN (MRE11-RAD50-NBS1) complex, promoting ATM 
checkpoint response and homologous recombination repair71. Since miR-506 
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negatively regulate RAD17, I hypothesized that miR-506 reintroduction could impair 
also ATM signalling activation occurring upon DNA damage recognition. In order to 
validate RAD17 new proposed role in my model of EOC I firstly silenced SKOV3 cells 
with siRAD17 and siCTRL siRNAs and upon DDP treatment I observed in RAD17 
silenced cells a reduced phosphorylation, thus activation, of ATM (Figure 23E, left 
panel). More importantly, when I ectopically expressed miR-506 in the same cell 
line, I obtained a reduced activation of ATM after DDP treatment (Figure 23E, right 
panel), similar to RAD17 silencing effect. These observations further support the 
important role of miR-506 and its regulation on RAD17 gene expression in DNA 
damage response and in promoting early ATM checkpoint response. Overall these 
results suggest that miR-506 may lead to a delayed recruitment of DNA damage 
proteins at damage sites and a delayed activation of signal cascade upon treatment.  
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Figure 23: miR-506 reintroduction impairs response to DNA damage 
A) Western blot analysis of γH2AX expression in SKOV3 cells transfected with miR-506 
mimic or scr control miR and treated with platinum (DDP). Lysates collected at 24 hours 
after treatment. Vinculin was used as loading control. Inset in the right panel representing 
RAD51 downregulation used as positive control of miR-506 transfection. B) Representative 
images of the immunofluorescence staining of γH2AX in SKOV3 transfected with miR-506 or 
scr control and treated with or without platinum at the concentration of 3 µM for 24h. 
Magnification 40X. C) Percentage of γH2AX-positive cells following DDP treatment at 3 µM. 
Cells with more then 15 foci were considered as γH2AX-positive. Data are mean ± SD of two 
experiments (** p<0.01). D) Western blot analysis of γH2AX expression in SKOV3 cells 
silenced for RAD17 and treated with platinum (DDP) at 1 and 3 µM. Vinculin was used as 
loading control. E) Western blot analysis of pATM expression upon DDP treatment in both 
miR-506 and scr transfected and siRAD17 and siCTRL silenced SKOV3 cells. β-actin was used 
as loading control. 
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4.14 MiR-506 causes a delay in platinum-induced G2 cell cycle arrest 
Sensing and repair of DNA damage are finely regulated events during cell cycle 
progression. G2/M cell cycle checkpoint is an important surveillance mechanism 
used by cells in response to DNA damage. Its function is to prevent entry into 
mitosis of damaged cells. Since miR-506 reintroduction was able to induce a 
possible delay in sensing DNA damage I decided to investigate the potential role of 
miR-506 in regulating progression of cell cycle in response to platinum treatment. 
SKOV3 cells were transfected with miR-506 mimic or scramble control miR and 
treated with DDP at the concentration of 1 µM and 3 µM. Cells were collected at 
different time points (24h, 48h and 72h) after treatment and their cell cycle 
analysed by FACS. As expected, gradual accumulation of cells blocked in S and G2/M 
phase of the cell cycle was evident over time in scr treated cells (Figure 24A, upper 
panels). MiR-506 reconstituted cells showed instead a marked delay in 
accumulation of cells in G2/M phase of the cell cycle particularly evident at 48 hours 
from DDP treatment compared to scr control cells (Figure 24A, lower panels) (25% 
versus 53% cells at G2/M phase for miR-506 and scr cells respectively, Figure 24B). 
After 72 hours of treatment however, both miR-506 and scr cells showed the same 
extent of block in G2/M phase (Figure 24B). These data suggested that miR-506 
reconstitution induced a delay in G2/M cell cycle arrest upon platinum treatment. 
This delay could allow cells to propagate into the cell cycle with an unrepaired 
extensive DNA damage with premature entry into mitosis which will cause cell 
death. 
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Figure 24: MiR-506 reconstitution affects cell cycle progression 
Flow cytometry analysis of the cell cycle distribution after DDP treatment in miR-506 and 
scr control transfected SKOV3 cells using propidium iodide staining. A) Representative 
images showing delayed accumulation of cells in phase G2/M of the cell cycle after 3 µM 
DDP treatment in miR-506 reconstituted cells (lower panels) compared to scr tranfected 
cells (upper panels). B) Quantification of cell cycle distribution in percentage during time 
(24h and 48h) upon 1 and 3 µM DDP treatment, with the percentage of cells in G1 phase 
(light grey), S phase (grey), and G2/M phase (dark gray). C) Quantification of cell cycle 
distribution following 72h of DDP treatment. 
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Since the observed effect in impairing the G2/M block of cells upon DDP treatment, 
I decided to assess if miR-506 reconstitution may cause major alterations in the 
signal transduction pathway activated upon DNA damage and related to cell cycle 
G2/M checkpoint activation. Western blot analysis revealed that in SKOV3 cells the 
ectopic expression of miR-506 drastically abrogated G2/M checkpoint activation 
signal cascade consistent with its role in delaying block of cells in G2/M phase of the 
cell cycle upon DDP treatment (Figure 25B). More in detail, I observed a reduction in 
phosphorylated Chk1 kinase in Serine 296, one of the DNA damage induced 
phosphorylation sites, which in turn abolished cyclin-B1-CDK1 complex activation, a 
key event that initiates mitotic entry. Indeed, upon miR-506 reconstitution, a 
reduction of cyclin-B1 levels was observed in treated cells and abrupt 
dephosphorylation of the inhibitory phosphorylation site of CDK1 (tyrosine 15, Y15). 
Moreover CDK1 remained dephosphorylated, thus active, also by the lack of the 
inhibitory phosphorylation exerted by Wee1 kinase. Indeed I observed a decreased 
expression and a proportional decreased activation (phosphorylation) of Wee1 
protein, which as well as Chk1 resulted impaired following miR-506 transfection. 
These results further support the role of miR-506 in abrogating G2/M checkpoint in 
response to DNA damage allowing the entry of damaged cells into mitosis. 
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Figure 25: Abrogation of G2/M cell cycle checkpoint in miR-506 reconstituted cells 
A) Schematic illustration of the main molecular actors involved in G2/M checkpoint 
activation. Upon DNA damage, Cyclin-B1-CDK1 complex is activated leading to activation of 
G2 checkpoint in order to block cell cycle before to give time to cells for repair their 
damage before enter in mitosis (M). Among key events, CDK1 is phosphorylated in its 
inhibitory phosphorylation site (Y15) mediated by Chk1 and Wee1 kinases. On the contrary, 
when Cyclin-B1 is degraded by ubiquitination (ub) and CDK1 dephosphorylated, the Cyclin-
B1-CDK1 complex is inactive and cells enter into M phase of the cell cycle. B) SKOV3 cells 
were transfected with miR-506 (506) or scr-miR (scr) and treated or not with 1 and 3 µM of 
platinum (DDP) for 24 and 48 hours, time points at which lysates were collected and 
western blot analysis was performed. Images are representatives of at least three 
experiments. Vinculin was used as loading control.  
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4.15 RAD17 is synthetically lethal with Chk1 and Wee1 inhibitors in EOC models 
in vitro 
In recent years many efforts are being made to map synthetic-lethal interactions in 
cancer for the design of targeted therapies in human cancers166. It has been shown 
by Shen and co-authors81 that RAD17 loss of function was synthetically lethal with 
Chk1 and Wee1 Inhibitors. In light of this evidence obtained in Hela and LN428 
cellular models displaying inactive p53, I wanted to verify if RAD17 suppression 
could reproduce the same effect in EOC model. For this purpose I silenced RAD17 
expression with siRNAs in SKOV3 p53null and OAW42 p53wt cell lines and I 
evaluated by clonogenic assays the effects of treatment with AZD1775, an inhibitor 
of Wee1 and with LY2603618, an inhibitor of Chk1 at different doses. Silencing 
efficacy was evaluated 72h after each transfection at protein level in both cell lines. 
The Wee1 Inhibitor AZD1775 was significantly more toxic in RAD17 depleted cells 
compared to control cells in both cell lines with a drop in the IC50 of 3.5 fold for 
SKOV3 and 2 fold for OAW42 (Figure 26 upper panels). RAD17 silencing induced the 
same significant effect of enhanced toxicity also upon treatment with the Chk1 
inhibitor LY2603618 in the same cell lines with a drop in the IC50 of 1.5 fold for 
SKOV3 and 3.5 fold for OAW42 (Figure 26 lower panels). These results suggest that 
depletion of RAD17 is involved in inducing synthetic lethal effect with checkpoint 
kinases inhibitors also in EOC model further supporting the concept that checkpoint 
kinases inhibitors could be most active in tumours with defects in DNA damage 
repair such as RAD17 loss of function. 
  
105 
 
 
Figure 26: Synthetic lethal effect of RAD17 depletion with checkpoint kinases inhibitors 
SKOV3 and OAW42 cell lines were silenced or not for RAD17 using siRNAs (siRAD17 or 
siCTRL) and seeded in 6 well plates for clonogenic assays. The day after transfection cells 
were treated with serial dilution of Wee1 inhibitor AZD1775 (upper panels) or the Chk1 
inhibitor LY2603618 (lower panels) at indicated concentrations. Percentage of relative 
colony formation rate of siRAD17 versus siCTRL transfected and treated cells were 
evaluated. Colonies were counted under optical microscope. Data are mean ± SD of at least 
three experiments. Two way ANOVA and Bonferroni’s post test was used to compare 
siRAD17 transfected cells versus siCTRL transfected cells (*p<0.05; ** p<0.01; ***p<0.001, 
****p<0.0001). 
 
 
 
 
 
0
5
0
1
0
0
1
5
0
2
0
0
3
0
0
0
2 0
4 0
6 0
8 0
1 0 0
L Y 2 6 0 3 6 1 8  [ n M ]
r
e
l
a
t
i
v
e
 
c
o
l
o
n
y
 
f
o
r
m
a
t
i
o
n
 
r
a
t
e
 
(
%
)
*
* * *
* * * *
* * * *
* * * *
0
2
5
5
0
1
0
0
0
2 0
4 0
6 0
8 0
1 0 0
L Y 2 6 0 3 6 1 8  [ n M ]
r
e
l
a
t
i
v
e
 
c
o
l
o
n
y
 
f
o
r
m
a
t
i
o
n
 
r
a
t
e
 
(
%
)
* * * *
* * *
* *
O A W 4 2
n
t
2
5
5
0
1
0
0
0
2 0
4 0
6 0
8 0
1 0 0
A Z D 1 7 7 5  [ n M ]
r
e
l
a
t
i
v
e
 
c
o
l
o
n
y
 
f
o
r
m
a
t
i
o
n
 
r
a
t
e
 
(
%
)
* * *
* * *
S K O V 3
0
5
0
1
0
0
1
5
0
0
2 0
4 0
6 0
8 0
1 0 0
s iC T R L
s i R A D 1 7
A Z D 1 7 7 5  [ n M ]
r
e
l
a
t
i
v
e
 
c
o
l
o
n
y
 
f
o
r
m
a
t
i
o
n
 
r
a
t
e
 
(
%
)
* * * *
* * * *
* * * *
106 
 
4.16 MiR-506 reintroduction causes synthetic lethality with Chk1 and Wee1 
Inhibitors resembling RAD17 silencing. 
Since RAD17 silencing was able to sensitise EOC cells to Chk1 and Wee1 inhibitors, I 
wanted to evaluate if reintroduction of miR-506, through modulation of RAD17 
expression, could reproduce the same effect of sensitiveness to these checkpoint 
kinases inhibitors. For this purpose SKOV3 and OAW42 cells transfected with miR-
506 mimic or the miR-scramble control were treated with the Wee1 inhibitor 
AZD1775, or with the Chk1 inhibitor LY2603618, at different doses and the 
treatment effects were evaluated by clonogenic assay. MiRNA transfection 
efficiency was evaluated 48h after transfection by qRT-PCR in both cell lines. 
Interestingly upon miR-506 reconstitution I was able to obtain a significant 
sensitisation to both Wee1 and Chk1 inhibitors in SKOV3 cell line (Figure 27, left 
panels) similar to what obtained following RAD17 depletion, with drop in the IC50 
of 1.6 fold for AZD1775 and 2 fold for LY2603618 compared to scr cells. MiR-506 
reconstitution in OAW42 cell line was synthetically lethal with the Wee1 inhibitor, 
with a drop in the IC50 of 1.5 fold compared to scr transfected cells, while no 
significant effect was observed upon treatment with the Chk1 inhibitor (Figure 27, 
right panels). These results indicate that miR-506 is able to sensitise EOC cells to 
Chk1 and Wee1 checkpoint kinases inhibitors resembling the effects induced by 
RAD17 silencing. Taken together these data highlight the important role of miR-506 
in regulating RAD17 expression and function, sustain a synthetic lethal approach 
based on RAD17 function and checkpoint kinases activity and also support the 
possibility of using miR-506 expression as a marker of response to checkpoint 
kinases inhibitors.   
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Figure 27: Synthetic lethality effects of miR-506 reconstitution with checkpoint kinases 
inhibitors 
SKOV3 and OAW42 cell lines were ectopically reconstituted with miR-506 mimic (506) or 
scramble miR (scr) and seeded in 6 well plates for clonogenic assays. The day after 
transfection, cells were treated with serial dilution of AZD1775, the Wee1 inhibitor (upper 
panels), or LY2603618, the Chk1 inhibitor (lower panels), at the indicated concentrations. 
Percentage of relative colony formation rate of miR-506 versus scr transfected cells were 
evaluated. Colonies were counted under optical microscope. Data are mean ± SD of at least 
three experiments. Two way ANOVA and Bonferroni’s post test was used to compare miR-
506 transfected cells versus scr transfected cells (*p<0.05; **p<0.01; ***p<0.001, 
****p<0.0001).  
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4.17 Combination of Chk1 or Wee1 inhibitors with platinum showed a 
synergistic effect in miR-506-reconstituted SKOV3 cells 
Platinum represents the standard of care for EOC patients but development of 
platinum resistance remains a major problem in the treatment of these patients. I 
then wanted to evaluate whether combination treatment strategies, combining 
platinum and checkpoint kinases inhibitors, could sensitise platinum-resistant cells. 
To this end I ectopically expressed miR-506 in the platinum resistant SKOV3 cell line 
and then I treated cells with the inhibitor of Wee1 AZD1775, or with the inhibitor of 
Chk1 LY2603618, alone or in combination with 0.5 µM of platinum (DDP) 
corresponding to the IC50. The data indicated that the combination of platinum and 
AZD1775, as well as platinum and LY2603618 were substantially more effective than 
mono-treatments in reducing colony formation rate. The reduction on IC50 due to 
treatment combination was evident in scr transfected cells from 200 nM to 135 nM 
for AZD1775 and from 450 nM to 300 nM for LY2603618. More important when 
miR-506 reconstituted cells were treated with combination therapy a dramatic 
effect was observed with an IC50 reduction of 60% (2 fold decrease) for both 
AZD1775/DDP and LY2603618/DDP combinations (Figure 28, left panels). Moreover 
the two combination treatments induced synergistic effect in miR-506 reconstituted 
cells compared with scr control cells as determined by combination index (CI) 
analysis (Figure 28, right panels). These results suggest that DDP-AZD1775/DDP-
LY2603618 combination treatments have an important effect on 
chemosensitisation in the setting of miR-506 expression compared to individual 
drugs and induced synergistic effects in miR-506 reconstituted SKOV3 resistant 
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cells. This could minimize drug concentrations and therefore reduce non-specific 
effects and general toxicity upon treatment. 
Figure 28: Inhibition on Wee1 or Chek1 in mR-506 reconstituted cells results in synergistic 
effect with platinum treatment. 
SKOV3 cell line was treated with platinum (DDP) (held constant at 0.5 µM) and AZD1775 or 
LY2603618 at different concentrations as reported in the graphs. Left panels: percentage 
colony formation rates of miR-506 reconstituted cells treated with AZD1775 and LY2603618 
alone or in combination with DDP (dashed lines). Data are mean ± SD of at least three 
experiments. Two way ANOVA and Bonferroni’s post test was used to compare miR-506 
transfected cells treated with AZD1775 or LY2603618 versus combinations with DDP 
(*p<0.05; **p<0.01; ***p<0.001, ****p<0.0001). Right panels: combination Index (CI) 
analysis was performed using the CompuSyn system. SKOV3 percentage colony formation 
rate were converted to growth inhibition (Fraction Affected, F) and plotted against CI. The 
first three doses for each checkpoint kinase inhibitor were plotted. Dotted blue lines on the 
graph designates a CI equal to 1 (dark blue line) and equal to 0.3 (light blue line). 
Combination Index indicates additivity when CI value is 1, antagonism when CI>1, 
synergism when CI<1 and strong synergism when CI<0.3. 
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5 Discussion 
The general aim of this thesis was to identify and better characterize the miRNA-
driven role in response to chemotherapy in EOC. EOC patients are usually diagnosed 
at advanced stages of the disease and often experience disease relapse with 
instauration of a chemotherapy resistant condition with a consequent poor 
prognosis1-3. One of the major challenges remains the identification of patients with 
increased risk of disease recurrence for the design of new therapeutic strategies to 
overcome resistance to treatment. To address these questions, genomic based 
approaches are needed to deeply characterize this highly heterogeneous disease at 
the molecular level. Molecular-driven approaches for EOC are recently becoming 
real therapeutic options in combination to platinum agents as in the case of the 
addition of the anti-angiogenic drug Bevacizumab167 or the use of PARP inhibitors in 
specific molecular subsets44, 168. MiRNAs, small non-coding RNAs that regulate gene 
expression at the post-transcriptional level, represent an important layer of 
information that could help to explain the behaviour of EOC tumour cells in 
different processes including chemoresponse124. In recent years my laboratory 
analysed the miRNA expression profiles in EOC patients identifying a cluster of eight 
miRNAs (ChrXq27.3 cluster) found to be downregulated in high grade advanced 
stage early relapsing patients144 and included in a miRNA-based predictor of early 
relapse143, suggesting a role of this cluster in disease progression and 
chemoresponse. I decided to focus on miR-506, belonging to the cluster, the most 
characterised miRNA and probably the driver of the cluster. I knew by previous 
works of my group that miR-506 was able to sensitise EOC cells to platinum 
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treatment in p53wt setting supporting its role in chemoresponse and in disease 
relapse144. In this thesis I have confirmed in two new EOC case cohorts previous 
observations. Searching for the appropriated cellular models I found that all the 
EOC cell lines tested presented very low levels of miR-506 expression, a 
characteristic shared with cell lines of histotypes different from ovary160-162. The low 
expression of miR-506 is a common feature also in EOC patients. Indeed previous 
analysis of my research group of the microRNA expression profiles in independent 
cohorts of EOC patients including the TCGA dataset showed that miR-506 was 
expressed at detectable levels only in 30% of patients143, 144. The association of low 
expression of miR-506 and of the entire cluster with patients’ early relapse supports 
its role as oncosuppressor miRNA.  
MiRNAs expression can be regulated by different mechanisms such as major 
genomic rearrangement, epigenetic events169-171 or transcription factor 
deregulations172. It is likely that such regulations are responsible for the low 
expression level I found in my cellular models and in patients. Interestingly 
ChrXq27.3 miRNAs cluster maps near to an X fragile site region, however no copy 
number variations of this region were detected in TCGA study148, and no studies on 
evaluation of presence of micro-deletion such as LOH have been performed so far. 
The most studied aspect is epigenetic regulation. Indeed, by analyzing EOC cell lines, 
in the promoter region of miR-506 Yang and co-workers identified five CpG sites, 
regions rich in cytosine that can be highly methylated, thus silenced, therefore 
changing gene expression levels. Treatment with demethylating agents such as 5-
aza-2’-deoxycytidine (5-Aza-dC) significantly restored miR-506 levels suggesting that 
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epigenetic silencing can be responsible for the low expression of miR-506 148. They 
were not able to evaluate the methylation status of the miR-506 promoter in the 
cohort of patients of the TCGA study due to the lack of the coverage of the 
ChrXq27.3 in the methylome platform used. However, by pyrosequencing analysis 
performed on an independent cohort of patients they identified a negative 
correlation between methylation and miR-506 expression although it was not 
statistically significant. Similar results were obtained by Li j and collaborators in the 
context of pancreatic cancer further indicating that DNA methylation contributes to 
miR-506 gene silencing153. Moreover binding sites of putative transcriptional factors 
have been identified in the promoter region of miR-506 family. In breast and lung 
cancer, a crosstalk between NF-kB and p53 was shown to regulate miR-506 
expression. However, the final effect (inhibitory or promoting) was dependent on 
the tumour type173 174. The causes of miR-506 deregulation in EOC have to be yet 
investigated. Indeed, given the peculiar way of growth and dissemination of EOC 
and the well known bidirectional communication between cancer cells and the 
tumour microenvironment175, it cannot be excluded also that paracrine signal from 
tumour microenvironment could play a role in regulation of miR-506 expression176. 
The improving in generation of organotypic tridimentional culture system that 
mimic the in vivo situation could help in elucidating the mechanisms responsible for 
miR-506 deregulation that need to be further investigated.  
Once defined that I could only rely on cellular models allowing gain of function 
experiments, I explored and confirmed the ability of miR-506 to re-sensitise to 
platinum treatment EOC cells with p53 mutational status. To investigate the role of 
113 
 
miR-506 in chemotherapy response and identify miR-506 target genes potentially 
involved in this process, I performed an in silico identification of putative miR-506 
target genes and related functions, using publicly available softwares. Besides genes 
involved in EMT such as SNAI2, VIM and N-CADH145, 148, I identified genes regulating 
DNA repair pathway such as RAD51, involved in homologous recombination repair, 
and RAD17 an early sensor of DNA damage. The mechanism of miR-506-RAD51 has 
already been explored147 while no data are available concerning RAD17 in EOC. I 
therefore concentrated on this miR-506-RAD17 regulatory axis, supposing its 
involvement in EOC response to therapy. After confirming that RAD17 was a direct 
target of miR-506, I showed that the platinum sensitisation induced by miR-506 
expression was related to RAD17 regulation. Indeed by performing RAD17 target 
protector experiments, I demonstrated that the miR-506 induced sensitisation to 
platinum treatment was directly depending on the possibility of miR-506 to regulate 
RAD17 expression. The effect, indeed, was lost when targeting of miR-506 was 
impaired by the target protection sequence. Moreover, being an early event in DDR 
and therefore acting upstream of many DDR molecules RAD17 could orchestrate 
the entire response. Importantly, I found RAD17 to be anti-correlated with miR-506 
expression in EOC patients, validating my in vitro results. As expected RAD17 
expression was associated with poor prognosis when I interrogated online available 
datasets suggesting its prognostic role and clinical relevance in EOC. Strongly in 
accordance with my finding, miR-506 expression was associated with EOC good 
prognosis147, 148. 
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DDR dependency in cancer is currently being exploited to generate new cancer 
therapeutic strategies. Recent findings demonstrated that PARP inhibitors, which 
act in the BER pathway by inhibiting PARP activity to sense and repair ssDNA breaks, 
which in turn can lead to dsDNA breaks177, are particularly effective in patients 
harbouring BRCA1/2 mutations. Indeed these patients display defects in HRR, a 
mechanism required for dsDNA repair. The contemporaneous blocking of both 
repair pathways lead to cell death by synthetic lethality. The use of PARP inhibitors 
represents one of the best examples of synthetic lethal approach in cancer for the 
management of significant subset of tumours including EOC57-59. It has to be taken 
into consideration that HRR deficiency has been observed also in EOC patients with 
loss of function of genes other than BRCA1/2 such as RAD51, ATM, ATR178, 179. These 
patients display a 'BRCAness' phenotype, characterised by the ability to respond to 
multiple platinum treatments, similar to that of BRCA1/2 mutated patients. Given 
the complexity of the DDR pathway and the crosstalk between the different DNA 
repair components involved in such pathway, it is likely that a single biomarker may 
not be sufficient to predict the benefit of PARP inhibitor therapies44. In this thesis I 
demonstrated that also miR-506-RAD17 axis was able to sensitise EOC cells to the 
PARP inhibitor olaparib. The involvement of RAD17 in inducing sensitisation to PARP 
inhibitors could be explained by recent findings on the new role proposed for 
RAD17 as necessary for activation of the ATM signalling pathway71, which promote 
HRR. Accordingly I found that miR-506 expression was able to impair ATM activation 
similar to RAD17 silencing. Thus miR-506, impairing HRR by acting on both RAD17 
and RAD51, could represent a possible new biomarker for the selection of patients 
115 
 
that can benefit from PARP inhibitors treatment. Indeed it would be very interesting 
to evaluate the expression of miR-506 in BRCA1/2 proficient EOC patients 
responding to PARP inhibitors. Accordingly also the loss of function of RAD17 could 
confer a BRCAness phenotype and therefore being considered a useful biomarker. 
The RAD17 mediated activation of MRN/ATM signalling cascade has been recently 
shown to contribute in maintaining genomic integrity71 and its depletion has been 
associated with genome instability in head and neck cancer73 and associated with 
DNA fragmentation and mitotic catastrophe180 in gemcitabine treated pancreatic 
cancer cells80, 165. In my cellular model I observed that sensitisation to platinum 
treatments induced by miR-506 expression was associated with aberrant mitotic 
figures and micronuclei formation resulting from asyncronous chromosomes 
segregation, which are correlated with mitotic catastrophe180. The actual 
contribution of miR-506 in this phenomenon is currently under investigation. I also 
found that miR-506 reintroduction caused an impairment and overall attenuation of 
DDR signalling in EOC cells following platinum treatment. This reduction could be 
due to a decreased RAD17 expression that in turn causes a delay in the recruitment 
of DDR proteins at damaged sites. I hypothesized that miR-506 expression, by 
regulating different molecules of the DDR involved in the correct propagation of the 
signal upon DNA damage, could deceive the tumour cell reducing its ability to 
properly sense the damage entity. Then, the cells would go ahead into the cycle in 
spite of their accumulating damages and will be finally committed to death. Indeed I 
demonstrated that miR-506 expression induced impairment in G2/M checkpoint 
activation with reduced accumulation of cells in G2 phase of the cell cycle following 
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platinum treatment by impairing the signalling pathway at the basis of the G2/M 
block. However the effects on G2 block was transitory, sustaining the hypothesis of 
a delay in activation of DNA repair mechanisms that may contribute to an increase 
of genomic instability with a subsequent sensitisation to DNA damaging drugs. 
The central role of RAD17 in DDR is highlighted also by recent studies on networks 
of synthetic-lethal interactions that identified RAD17 knockdown to be synthetically 
lethal with different tumour suppressor and druggable genes81, 166. In this thesis I 
demonstrated that RAD17 silencing, besides being synthetically lethal with PARP 
inhibitors, exerted the same effects with Chk1 and Wee1 Checkpoint kinases 
inhibitors and, accordingly, miR-506 expression induced the same synthetic lethal 
effect. As expected the synthetic lethality observed in the context of p53null cell 
line was more efficient than in a p53wt context181. This could be explained by the 
fact that cancer cells which retain p53 function can activate a series of mechanisms 
in response to DNA damage insults, like cell cycle arrest in G1 phase. p53 mutated 
cells loose this ability therefore targeting G2/M checkpoint in p53 mutated setting 
can be a valid therapeutic alternative strategy particularly in HGSOCs patients which 
display a near universal p53 aberration. The two checkpoint kinases inhibitors that I 
used in this thesis are selective for the proteins they targets with reduced possibility 
of off-target effects. This characteristic makes these drugs particularly attractive for 
cancer therapy. In particular the Wee1 inhibitor is currently in clinical development 
in combination with chemotherapy in patients with platinum-resistant EOC 
(NCT02272790). 
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Of note I identified also WEE1 and CHEK1 among the putative miR-506 predicted 
target genes. Therefore, it cannot be exclude that the miR-506 induced sensitivity to 
Chk1 and Wee1 checkpoint kinases inhibitors could be a results of the 
combinatorial effect of miR-506 targeting on different molecules that regulate DNA 
damage repair pathway at different levels. All together these findings suggest miR-
506 to be a key node in the regulation of DDR in response to drug treatments.  
Reduce the general toxicity and over treatment of EOC patients still remain a 
problem. I demonstrated that the combination treatment of platinum with Chk1 
and Wee1 checkpoint kinases inhibitors resulted to be more effective than mono 
treatments in EOC cells and synergistic in the context of miR-506 expression. This 
combinatorial effect may potentiate drug clinical efficacy with the consequent 
reduction in general toxicity182, 183.  
MiR-506 pleiotropic effects on DDR pathway need to be better clarified and lay the 
ground to future studies aimed to identify all the possible synthetic lethal pairs that 
can be therapeutically targeted. 
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6 Conclusions and Future perspectives 
The work presented in this thesis highlighted the importance of miR-506 as a 
chemosensitizing miRNA in EOC acting as a key node in the regulation of DNA 
damage response pathway. The identification of a new miR-506-RAD17 axis could 
represent a new biomarker to be proposed as selection criteria for patients 
susceptible to DNA damaging drugs in combination with different new small 
molecules that target DDR. 
Since I have observed that expression of miR-506 in platinum treated cells caused 
mitotic defects and micronuclei appearance, the occurrence of mitotic cell death by 
mitotic catastrophe, as final outcome, remain to be assessed. Time lapse 
microscopy analysis (live imaging) on EOC cells will be performed in order to 
monitor cell division and cell fate in the setting of miR-506 expression and drug 
treatment. 
To assess the important role of the miR-506-RAD17 axis in EOC, the effects of its 
modulation will be assessed in additional cell lines representative of high grade 
serous ovarian cancer and in patients’ derived cells as more appropriated model. 
Since its pleiotropic role in modulating different molecules of the DDR pathway, I 
will better define the miR-506-driven molecular mechanisms related to sensitisation 
to drug treatments on different target genes. In particular the assessment of the 
direct targeting of miR-506 on WEE1 and CHEK1 by luciferase assay will be tested.  
RAD17 expression at protein level will be assessed by IHC analysis in EOC tissues 
from datasets already profiled for miRNA expression in order to correlate miR-506 
and RAD17 expression  
119 
 
List of publications during PhD 
Bagnoli M, Granata A, Nicoletti R, Krishnamachary B, Bhujwalla ZM, Canese R, Podo 
F, Canevari S, Iorio E, Mezzanzanica D. Choline Metabolism Alteration: A Focus on 
Ovarian Cancer Front Oncol. 2016 Jun 22 
- Cocco E, Shapiro EM, Gasparrini S, Lopez S, Schwab CL, Bellone S, Bortolomai I, 
Sumi NJ, Bonazzoli E, Nicoletti R, Deng Y, Saltzman WM, Zeiss CJ, Centritto F, Black 
JD, Silasi DA, Ratner E, Azodi M, Rutherford TJ, Schwartz PE, Pecorelli S, Santin AD. 
Clostridium Perfringens Enterotoxin C-terminal domain labeled to fluorescent Dyes 
for in vivo visualization of micro-metastatic chemotherapy-resistant ovarian cancer. 
Int J Cancer. 2015 Jun 9. 
- Granata A, Nicoletti R, Perego P, Iorio E, Krishnamachary B, Benigni F, Ricci A, Podo 
F, Bhujwalla ZM, Canevari S, Bagnoli M and Mezzanzanica D. Global metabolic 
profile identifies choline kinase alpha as a key regulator of glutathione-dependent 
antioxidant cell defense in ovarian carcinoma. Oncotarget. 2015 Mar 14. 
- Nicoletti R, Lopez S, Bellone S, Cocco E, Schwab CL, Black JD, Centritto F, Zhu L, 
Bonazzoli E, Buza N, Hui P, Mezzanzanica D, Canevari S, Schwartz PE, Rutherford TJ, 
Santin AD. T-DM1, a novel antibody-drug conjugate, is highly effective against 
uterine and ovarian carcinosarcomas overexpressing HER2. Clin Exp Metastasis. 
2015 Jan. 
- Schwab CL, Bellone S, English DP, Roque DM, Lopez S, Cocco E, Nicoletti R, 
Bortolomai I, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. 
Afatinib demonstrates remarkable activity against HER2-amplified uterine serous 
endometrial cancer in vitro and in vivo. Br J Cancer. 2014 Oct 28 
- Schwab CL, English DP, Roque DM, Bellone S, Lopez S, Cocco E, Nicoletti R, 
Rutherford TJ, Schwartz PE, Santin AD. Neratinib shows efficacy in the treatment of 
HER2/neu amplified uterine serous carcinoma in vitro and in vivo. Gynecol Oncol. 
2014 Oct  
 
 
120 
 
 Acknowledgements 
I would like to express my deepest appreciation to all who have provided me the 
support and invaluable guidance through the years of this PhD program. A special 
gratitude I give particularly to my Director of Study, Dr. Delia Mezzanzanica, for all 
the advice and constant financial support in my scientific work. She has been a very 
good advisor who brings out the optimism in me. My most sincere thanks to my 
supervisor Dr Marina Bagnoli and Prof Iain McNeish for their support and guidance 
while carrying out my work.  
I thank my old and new fellow labmates, in particular Barbara, Katia, Francesca, 
Anna, Alessandro and Francesco for their support and for all the fun we have had in 
the last years. I would like to thanks to my friends, near and far, who have 
supported me throughout the process.  
Last, but definitely not the least, a big thank you to my family: my parents and my 
sister for supporting me spiritually throughout these years and my life in general. A 
huge thank you goes to my boyfriend. He supported me with love and patience and 
helped me to keep things in perspective. I deeply appreciate his belief in me. I 
dedicate this thesis to him. 
  
121 
 
Bibliography 
 
 
122 
 
References  
1. Jayson, G. C., Kohn, E. C., Kitchener, H. C. & Ledermann, J. A. Ovarian cancer Lancet 
384, 1376-1388 (2014).  
2. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer Statistics, 2017 CA Cancer. J. Clin. 67, 7-30 
(2017).  
3. Buys, S. S. et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, 
Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial JAMA 305, 
2295-2303 (2011).  
4. Markman, M. & Bookman, M. A. Second-line treatment of ovarian cancer Oncologist 5, 
26-35 (2000).  
5. Chen, V. W. et al. Pathology and classification of ovarian tumors Cancer 97, 2631-2642 
(2003).  
6. Ledermann, J. A. et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: 
ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann. Oncol. 24 
Suppl 6, vi24-32 (2013).  
7. Nik, N. N., Vang, R., Shih, I. & Kurman, R. J. Origin and pathogenesis of pelvic (ovarian, 
tubal, and primary peritoneal) serous carcinoma Annu. Rev. Pathol. 9, 27-45 (2014).  
8. Shih, I. & Kurman, R. J. Ovarian tumorigenesis: a proposed model based on 
morphological and molecular genetic analysis Am. J. Pathol. 164, 1511-1518 (2004).  
9. Kurman, R. J. & Shih, I. Molecular pathogenesis and extraovarian origin of epithelial 
ovarian cancer--shifting the paradigm Hum. Pathol. 42, 918-931 (2011).  
10. Tothill, R. W. et al. Novel molecular subtypes of serous and endometrioid ovarian 
cancer linked to clinical outcome Clin. Cancer Res. 14, 5198-5208 (2008).  
11. Kurman, R. J. & Shih, I. The Dualistic Model of Ovarian Carcinogenesis: Revisited, 
Revised, and Expanded Am. J. Pathol. 186, 733-747 (2016).  
12. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian 
carcinoma Nature 474, 609-615 (2011).  
13. Ahmed, A. A. et al. Driver mutations in TP53 are ubiquitous in high grade serous 
carcinoma of the ovary J. Pathol. 221, 49-56 (2010).  
14. Karst, A. M. & Drapkin, R. Ovarian cancer pathogenesis: a model in evolution J. Oncol. 
2010, 932371 (2010).  
123 
 
15. Labidi-Galy, S. I. et al. High grade serous ovarian carcinomas originate in the fallopian 
tube Nat. Commun. 8, 1093-017-00962-1 (2017).  
16. Hao, D. et al. Integrated Analysis Reveals Tubal- and Ovarian-Originated Serous 
Ovarian Cancer and Predicts Differential Therapeutic Responses Clin. Cancer Res. 23, 
7400-7411 (2017).  
17. Ayhan, A. et al. Defining the cut point between low-grade and high-grade ovarian 
serous carcinomas: a clinicopathologic and molecular genetic analysis Am. J. Surg. Pathol. 
33, 1220-1224 (2009).  
18. Vaughan, S. et al. Rethinking ovarian cancer: recommendations for improving 
outcomes Nat. Rev. Cancer. 11, 719-725 (2011).  
19. Kobel, M., Huntsman, D. & Gilks, C. B. Critical molecular abnormalities in high-grade 
serous carcinoma of the ovary Expert Rev. Mol. Med. 10, e22 (2008).  
20. du Bois, A. et al. Role of surgical outcome as prognostic factor in advanced epithelial 
ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 
multicenter trials. Cancer 115, 1234-1244 (2009).  
21. Kelland, L. R. et al. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-
cyclohexylamine platinum(IV): an orally active platinum drug Cancer Res. 53, 2581-2586 
(1993).  
22. Cohen, S. M. & Lippard, S. J. Cisplatin: from DNA damage to cancer chemotherapy 
Prog. Nucleic Acid Res. Mol. Biol. 67, 93-130 (2001).  
23. Bellon, S. F., Coleman, J. H. & Lippard, S. J. DNA unwinding produced by site-specific 
intrastrand cross-links of the antitumor drug cis-diamminedichloroplatinum(II) 
Biochemistry 30, 8026-8035 (1991).  
24. Shuck, S. C., Short, E. A. & Turchi, J. J. Eukaryotic nucleotide excision repair: from 
understanding mechanisms to influencing biology Cell Res. 18, 64-72 (2008).  
25. Vaisman, A. et al. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and 
oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts Cancer 
Res. 58, 3579-3585 (1998).  
26. Jackson, S. P. & Bartek, J. The DNA-damage response in human biology and disease 
Nature 461, 1071-1078 (2009).  
27. Galluzzi, L. et al. Molecular mechanisms of cisplatin resistance. Oncogene 31, 1869 
(2011).  
28. Dabholkar, M. et al. ERCC1 and ERCC2 expression in malignant tissues from ovarian 
cancer patients J. Natl. Cancer Inst. 84, 1512-1517 (1992).  
124 
 
29. Weberpals, J. et al. The DNA repair proteins BRCA1 and ERCC1 as predictive markers 
in sporadic ovarian cancer Int. J. Cancer 124, 806-815 (2009).  
30. Aebi, S. et al. Loss of DNA mismatch repair in acquired resistance to cisplatin Cancer 
Res. 56, 3087-3090 (1996).  
31. Brown, R. et al. hMLH1 expression and cellular responses of ovarian tumour cells to 
treatment with cytotoxic anticancer agents Oncogene 15, 45-52 (1997).  
32. Drummond, J. T., Anthoney, A., Brown, R. & Modrich, P. Cisplatin and adriamycin 
resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian 
tumor cell line J. Biol. Chem. 271, 19645-19648 (1996).  
33. Gifford, G., Paul, J., Vasey, P. A., Kaye, S. B. & Brown, R. The acquisition of hMLH1 
methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer 
patients Clin. Cancer Res. 10, 4420-4426 (2004).  
34. Alsop, K. et al. BRCA Mutation Frequency and Patterns of Treatment Response in 
BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian 
Ovarian Cancer Study Group. JCO 30, 2654-2663 (2012).  
35. Yang, D. et al. Association of BRCA1 and BRCA2 mutations with survival, 
chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer 
JAMA 306, 1557-1565 (2011).  
36. Edwards, S. L. et al. Resistance to therapy caused by intragenic deletion in BRCA2 
Nature 451, 1111-1115 (2008).  
37. Dhillon, K. K., Swisher, E. M. & Taniguchi, T. Secondary mutations of BRCA1/2 and 
drug resistance Cancer. Sci. 102, 663-669 (2011).  
38. Sakai, W. et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-
mutated cancers Nature 451, 1116-1120 (2008).  
39. Holzer, A. K. & Howell, S. B. The internalization and degradation of human copper 
transporter 1 following cisplatin exposure Cancer Res. 66, 10944-10952 (2006).  
40. Kilari, D., Guancial, E. & Kim, E. S. Role of copper transporters in platinum resistance 
World J. Clin. Oncol. 7, 106-113 (2016).  
41. Samimi, G. et al. Increased expression of the copper efflux transporter ATP7A 
mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells Clin. 
Cancer Res. 10, 4661-4669 (2004).  
42. Safaei, R. et al. Cross-resistance to cisplatin in cells with acquired resistance to copper 
Cancer Chemother. Pharmacol. 53, 239-246 (2004).  
125 
 
43. Patch, A. M. et al. Whole-genome characterization of chemoresistant ovarian cancer 
Nature 521, 489-494 (2015).  
44. Mirza, M. R. et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent 
Ovarian Cancer N. Engl. J. Med. 375, 2154-2164 (2016).  
45. Ledermann, J. et al. Olaparib maintenance therapy in patients with platinum-sensitive 
relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA 
status in a randomised phase 2 trial. The Lancet Oncology 15, 852-861.  
46. Swisher, E. M. et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian 
carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial Lancet 
Oncol. 18, 75-87 (2017).  
47. Coleman, R. L. et al. Rucaparib maintenance treatment for recurrent ovarian 
carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, 
placebo-controlled, phase 3 trial. The Lancet 390, 1949-1961.  
48. Lord, C. J. & Ashworth, A. BRCAness revisited Nat. Rev. Cancer. 16, 110-120 (2016).  
49. Turner, N., Tutt, A. & Ashworth, A. Hallmarks of 'BRCAness' in sporadic cancers Nat. 
Rev. Cancer. 4, 814-819 (2004).  
50. Walsh, T. et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and 
peritoneal carcinoma identified by massively parallel sequencing Proc. Natl. Acad. Sci. U. 
S. A. 108, 18032-18037 (2011).  
51. Tung, N. et al. Counselling framework for moderate-penetrance cancer-susceptibility 
mutations Nat. Rev. Clin. Oncol. 13, 581-588 (2016).  
52. Carmeliet, P. & Jain, R. K. Principles and mechanisms of vessel normalization for 
cancer and other angiogenic diseases Nat. Rev. Drug Discov. 10, 417-427 (2011).  
53. Jain, R. K. Normalizing tumor microenvironment to treat cancer: bench to bedside to 
biomarkers J. Clin. Oncol. 31, 2205-2218 (2013).  
54. Kasparek, T. R. & Humphrey, T. C. DNA double-strand break repair pathways, 
chromosomal rearrangements and cancer Semin. Cell Dev. Biol. 22, 886-897 (2011).  
55. Ciccia, A. & Elledge, S. J. The DNA damage response: making it safe to play with knives 
Mol. Cell 40, 179-204 (2010).  
56. Polo, S. E. & Jackson, S. P. Dynamics of DNA damage response proteins at DNA breaks: 
a focus on protein modifications Genes Dev. 25, 409-433 (2011).  
57. Uziel, T. et al. Requirement of the MRN complex for ATM activation by DNA damage 
EMBO J. 22, 5612-5621 (2003).  
126 
 
58. Flynn, R. L. & Zou, L. ATR: a master conductor of cellular responses to DNA replication 
stress Trends Biochem. Sci. 36, 133-140 (2011).  
59. Chapman, J. R., Taylor, M. R. & Boulton, S. J. Playing the end game: DNA double-
strand break repair pathway choice Mol. Cell 47, 497-510 (2012).  
60. Schwartz, G. K. & Shah, M. A. Targeting the cell cycle: a new approach to cancer 
therapy J. Clin. Oncol. 23, 9408-9421 (2005).  
61. Bartek, J. & Lukas, J. Mammalian G1- and S-phase checkpoints in response to DNA 
damage Curr. Opin. Cell Biol. 13, 738-747 (2001).  
62. Smits, V. A. & Medema, R. H. Checking out the G(2)/M transition Biochim. Biophys. 
Acta 1519, 1-12 (2001).  
63. Ishikawa, K., Ishii, H. & Saito, T. DNA damage-dependent cell cycle checkpoints and 
genomic stability DNA Cell Biol. 25, 406-411 (2006).  
64. Lin, A. B., McNeely, S. C. & Beckmann, R. P. Achieving Precision Death with Cell-Cycle 
Inhibitors that Target DNA Replication and Repair Clin. Cancer Res. 23, 3232-3240 (2017).  
65. Benada, J. & Macurek, L. Targeting the Checkpoint to Kill Cancer Cells Biomolecules 5, 
1912-1937 (2015).  
66. von Deimling, F. et al. Human and mouse RAD17 genes: identification, localization, 
genomic structure and histological expression pattern in normal testis and seminoma 
Hum. Genet. 105, 17-27 (1999).  
67. Bluyssen, H. A. et al. Human and mouse homologs of the Schizosaccharomyces pombe 
rad17+ cell cycle checkpoint control gene Genomics 55, 219-228 (1999).  
68. Zou, L., Cortez, D. & Elledge, S. J. Regulation of ATR substrate selection by Rad17-
dependent loading of Rad9 complexes onto chromatin Genes Dev. 16, 198-208 (2002).  
69. Navadgi-Patil, V. M. & Burgers, P. M. A tale of two tails: activation of DNA damage 
checkpoint kinase Mec1/ATR by the 9-1-1 clamp and by Dpb11/TopBP1 DNA Repair 
(Amst) 8, 996-1003 (2009).  
70. Mohni, K. N., Smith, S., Dee, A. R., Schumacher, A. J. & Weller, S. K. Herpes simplex 
virus type 1 single strand DNA binding protein and helicase/primase complex disable 
cellular ATR signaling PLoS Pathog. 9, e1003652 (2013).  
71. Wang, Q. et al. Rad17 recruits the MRE11-RAD50-NBS1 complex to regulate the 
cellular response to DNA double-strand breaks EMBO J. 33, 862-877 (2014).  
72. Paull, T. T. & Lee, J. H. Rad17, the clamp loader that loads more than clamps EMBO J. 
33, 783-785 (2014).  
127 
 
73. Zhao, M., Begum, S., Ha, P. K., Westra, W. & Califano, J. Downregulation of RAD17 in 
head and neck cancer Head Neck 30, 35-42 (2008).  
74. Bao, S. et al. ATR/ATM-mediated phosphorylation of human Rad17 is required for 
genotoxic stress responses Nature 411, 969-974 (2001).  
75. Kataoka, A. et al. Overexpression of HRad17 mRNA in human breast cancer: 
correlation with lymph node metastasis Clin. Cancer Res. 7, 2815-2820 (2001).  
76. Sasaki, H. et al. Overexpression of Hrad17 gene in non-small cell lung cancers 
correlated with lymph node metastasis Lung Cancer 34, 47-52 (2001).  
77. Zhang, S. et al. Clinically relevant microRNAs in ovarian cancer Mol. Cancer. Res. 13, 
393-401 (2015).  
78. Johannsdottir, H. K. et al. Chromosome 5 imbalance mapping in breast tumors from 
BRCA1 and BRCA2 mutation carriers and sporadic breast tumors Int. J. Cancer 119, 1052-
1060 (2006).  
79. Peng, H. Q., Liu, L., Goss, P. E., Bailey, D. & Hogg, D. Chromosomal deletions occur in 
restricted regions of 5q in testicular germ cell cancer Oncogene 18, 3277-3283 (1999).  
80. Fredebohm, J., Wolf, J., Hoheisel, J. D. & Boettcher, M. Depletion of RAD17 sensitizes 
pancreatic cancer cells to gemcitabine J. Cell. Sci. 126, 3380-3389 (2013).  
81. Shen, J. P. et al. Chemogenetic profiling identifies RAD17 as synthetically lethal with 
checkpoint kinase inhibition Oncotarget 6, 35755-35769 (2015).  
82. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation Cell 144, 646-
674 (2011).  
83. Curtin, N. J. DNA repair dysregulation from cancer driver to therapeutic target Nat. 
Rev. Cancer. 12, 801-817 (2012).  
84. Kobel, M. et al. The biological and clinical value of p53 expression in pelvic high-grade 
serous carcinomas J. Pathol. 222, 191-198 (2010).  
85. Hosoya, N. & Miyagawa, K. Targeting DNA damage response in cancer therapy Cancer. 
Sci. 105, 370-388 (2014).  
86. Thorstenson, Y. R. et al. Contributions of ATM mutations to familial breast and ovarian 
cancer Cancer Res. 63, 3325-3333 (2003).  
87. Song, H. et al. Contribution of Germline Mutations in the RAD51B, RAD51C, and 
RAD51D Genes to Ovarian Cancer in the Population J. Clin. Oncol. 33, 2901-2907 (2015).  
128 
 
88. Pearl, L. H., Schierz, A. C., Ward, S. E., Al-Lazikani, B. & Pearl, F. M. Therapeutic 
opportunities within the DNA damage response Nat. Rev. Cancer. 15, 166-180 (2015).  
89. Benada, J., Burdova, K., Lidak, T., von Morgen, P. & Macurek, L. Polo-like kinase 1 
inhibits DNA damage response during mitosis Cell. Cycle 14, 219-231 (2015).  
90. O'Neil, N. J., Bailey, M. L. & Hieter, P. Synthetic lethality and cancer Nat. Rev. Genet. 
18, 613-623 (2017).  
91. Konecny, G. E. & Kristeleit, R. S. PARP inhibitors for BRCA1/2-mutated and sporadic 
ovarian cancer: current practice and future directions Br. J. Cancer 115, 1157-1173 (2016).  
92. Rottenberg, S. et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP 
inhibitor AZD2281 alone and in combination with platinum drugs Proc. Natl. Acad. Sci. U. 
S. A. 105, 17079-17084 (2008).  
93. Helleday, T., Petermann, E., Lundin, C., Hodgson, B. & Sharma, R. A. DNA repair 
pathways as targets for cancer therapy Nat. Rev. Cancer. 8, 193-204 (2008).  
94. Morales, J. et al. Review of poly (ADP-ribose) polymerase (PARP) mechanisms of 
action and rationale for targeting in cancer and other diseases Crit. Rev. Eukaryot. Gene 
Expr. 24, 15-28 (2014).  
95. Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA 
mutation carriers N. Engl. J. Med. 361, 123-134 (2009).  
96. Banerjee, S. & Kaye, S. B. New strategies in the treatment of ovarian cancer: current 
clinical perspectives and future potential Clin. Cancer Res. 19, 961-968 (2013).  
97. 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/10
/news_detail_002196.jsp&mid=WC0b01ac058004d5c1.  
98. Pignata S et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal 
doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 
randomized phase III trial. J Clin Oncol. 29(27):3628-35 (2011) 
99. Audeh, M. W. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients 
with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial 
Lancet 376, 245-251 (2010).  
100. Wiggans, A. J., Cass, G. K., Bryant, A., Lawrie, T. A. & Morrison, J. Poly(ADP-ribose) 
polymerase (PARP) inhibitors for the treatment of ovarian cancer Cochrane Database 
Syst. Rev. (5):CD007929. doi, CD007929 (2015).  
129 
 
101. Gelmon, K. A. et al. Olaparib in patients with recurrent high-grade serous or poorly 
differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, 
open-label, non-randomised study. The Lancet Oncology 12, 852-861.  
102. Iglehart, J. D. & Silver, D. P. Synthetic lethality--a new direction in cancer-drug 
development N. Engl. J. Med. 361, 189-191 (2009).  
103. Macheret, M. & Halazonetis, T. D. DNA replication stress as a hallmark of cancer 
Annu. Rev. Pathol. 10, 425-448 (2015).  
104. Toledo, L. I. et al. ATR prohibits replication catastrophe by preventing global 
exhaustion of RPA Cell 155, 1088-1103 (2013).  
105. Petermann, E., Woodcock, M. & Helleday, T. Chk1 promotes replication fork 
progression by controlling replication initiation Proc. Natl. Acad. Sci. U. S. A. 107, 16090-
16095 (2010).  
106. Beck, H. et al. Cyclin-dependent kinase suppression by WEE1 kinase protects the 
genome through control of replication initiation and nucleotide consumption Mol. Cell. 
Biol. 32, 4226-4236 (2012).  
107. O'Connor, M. J. Targeting the DNA Damage Response in Cancer Mol. Cell 60, 547-560 
(2015).  
108. Jossé, R. et al. ATR Inhibitors VE-821 and VX-970 Sensitize Cancer Cells to 
Topoisomerase I Inhibitors by Disabling DNA Replication Initiation and Fork Elongation 
Responses. Cancer Res. 74, 6968-6979 (2014).  
109. Erice, O. et al. MGMT Expression Predicts PARP-Mediated Resistance to 
Temozolomide Mol. Cancer. Ther. 14, 1236-1246 (2015).  
110. Leijen, S. et al. Phase I/II study with ruthenium compound NAMI-A and gemcitabine 
in patients with non-small cell lung cancer after first line therapy. Invest. New Drugs 33, 
201-214 (2015).  
111. Catalanotto, C., Cogoni, C. & Zardo, G. MicroRNA in Control of Gene Expression: An 
Overview of Nuclear Functions Int. J. Mol. Sci. 17, 10.3390/ijms17101712 (2016).  
112. Kim, V. N. & Nam, J. W. Genomics of microRNA Trends Genet. 22, 165-173 (2006).  
113. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function Cell 116, 
281-297 (2004).  
114. Barca-Mayo, O. & Lu, Q. R. Fine-Tuning Oligodendrocyte Development by microRNAs 
Front. Neurosci. 6, 13 (2012).  
130 
 
115. Croce, C. M. Causes and consequences of microRNA dysregulation in cancer Nat. 
Rev. Genet. 10, 704-714 (2009).  
116. Garzon, R., Calin, G. A. & Croce, C. M. MicroRNAs in Cancer Annu. Rev. Med. 60, 167-
179 (2009).  
117. Lu, J. et al. MicroRNA expression profiles classify human cancers Nature 435, 834-
838 (2005).  
118. Esquela-Kerscher, A. & Slack, F. J. Oncomirs - microRNAs with a role in cancer Nat. 
Rev. Cancer. 6, 259-269 (2006).  
119. Visone, R. & Croce, C. M. MiRNAs and cancer Am. J. Pathol. 174, 1131-1138 (2009).  
120. Calin, G. A. et al. Frequent deletions and down-regulation of micro- RNA genes 
miR15 and miR16 at 13q14 in chronic lymphocytic leukemia Proc. Natl. Acad. Sci. U. S. A. 
99, 15524-15529 (2002).  
121. Tagawa, H. & Seto, M. A microRNA cluster as a target of genomic amplification in 
malignant lymphoma Leukemia 19, 2013-2016 (2005).  
122. Hayashita, Y. et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in 
human lung cancers and enhances cell proliferation Cancer Res. 65, 9628-9632 (2005).  
123. Svoronos, A. A., Engelman, D. M. & Slack, F. J. OncomiR or Tumor Suppressor? The 
Duplicity of MicroRNAs in Cancer Cancer Res. 76, 3666-3670 (2016).  
124. Mezzanzanica, D., Bagnoli, M., De Cecco, L., Valeri, B. & Canevari, S. Role of 
microRNAs in ovarian cancer pathogenesis and potential clinical implications Int. J. 
Biochem. Cell Biol. 42, 1262-1272 (2010).  
125. Corney, D. C. & Nikitin, A. Y. MicroRNA and ovarian cancer Histol. Histopathol. 23, 
1161-1169 (2008).  
126. Dahiya, N. & Morin, P. J. MicroRNAs in ovarian carcinomas Endocr. Relat. Cancer 17, 
F77-89 (2010).  
127. Iorio, M. V. et al. MicroRNA signatures in human ovarian cancer Cancer Res. 67, 
8699-8707 (2007).  
128. Zhang, L. et al. Genomic and epigenetic alterations deregulate microRNA expression 
in human epithelial ovarian cancer Proc. Natl. Acad. Sci. U. S. A. 105, 7004-7009 (2008).  
129. Vang, S. et al. Identification of ovarian cancer metastatic miRNAs PLoS One 8, e58226 
(2013).  
131 
 
130. Turchinovich, A., Samatov, T. R., Tonevitsky, A. G. & Burwinkel, B. Circulating 
miRNAs: cell-cell communication function? Front. Genet. 4, 119 (2013).  
131. Turchinovich, A., Weiz, L. & Burwinkel, B. Extracellular miRNAs: the mystery of their 
origin and function Trends Biochem. Sci. 37, 460-465 (2012).  
132. Lawrie, C. H. et al. Detection of elevated levels of tumour-associated microRNAs in 
serum of patients with diffuse large B-cell lymphoma Br. J. Haematol. 141, 672-675 
(2008).  
133. Li, H. et al. MicroRNA screening identifies circulating microRNAs as potential 
biomarkers for osteosarcoma Oncol. Lett. 10, 1662-1668 (2015).  
134. Le Large, T. Y. et al. Circulating microRNAs as diagnostic biomarkers for pancreatic 
cancer Expert Rev. Mol. Diagn. 15, 1525-1529 (2015).  
135. Mitchell, P. S. et al. Circulating microRNAs as stable blood-based markers for cancer 
detection Proc. Natl. Acad. Sci. U. S. A. 105, 10513-10518 (2008).  
136. Cortez, M. A., Welsh, J. W. & Calin, G. A. Circulating microRNAs as noninvasive 
biomarkers in breast cancer Recent Results Cancer Res. 195, 151-161 (2012).  
137. Yu, X., Odenthal, M. & Fries, J. W. Exosomes as miRNA Carriers: Formation-Function-
Future Int. J. Mol. Sci. 17, 10.3390/ijms17122028 (2016).  
138. Elias, K. M. et al. Diagnostic potential for a serum miRNA neural network for 
detection of ovarian cancer Elife 6, 10.7554/eLife.28932 (2017).  
139. Nam, E. J. et al. MicroRNA expression profiles in serous ovarian carcinoma Clin. 
Cancer Res. 14, 2690-2695 (2008).  
140. Marchini, S. et al. Association between miR-200c and the survival of patients with 
stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue 
collections. The Lancet Oncology 12, 273-285.  
141. Tang, Z., Ow, G. S., Thiery, J. P., Ivshina, A. V. & Kuznetsov, V. A. Meta-analysis of 
transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts 
molecular and clinical subclasses in high-grade serous ovarian carcinoma. International 
Journal of Cancer 134, 306-318 (2014).  
142. Calura, E. et al.  
A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the 
poor prognosis assessment. Annals of Oncology 27, 1511--1519 (2016).  
143. Bagnoli, M. et al. Development and validation of a microRNA-based signature 
(MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort 
study. The Lancet Oncology 17, 1137-1146 (2016).  
132 
 
144. Bagnoli, M. et al. Identification of a chrXq27.3 microRNA cluster associated with 
early relapse in advanced stage ovarian cancer patients Oncotarget 2, 1265-1278 (2011).  
145. Sun, Y. et al. MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal 
transition network and is associated with good prognosis in epithelial ovarian cancer J. 
Pathol. 235, 25-36 (2015).  
146. Liu, G. et al. MiR-506 suppresses proliferation and induces senescence by directly 
targeting the CDK4/6-FOXM1 axis in ovarian cancer J. Pathol. 233, 308-318 (2014).  
147. Liu, G. et al. Augmentation of response to chemotherapy by microRNA-506 through 
regulation of RAD51 in serous ovarian cancers J. Natl. Cancer Inst. 107, 
10.1093/jnci/djv108. Print 2015 Jul (2015).  
148. Yang, D. et al. Integrated analyses identify a master microRNA regulatory network 
for the mesenchymal subtype in serous ovarian cancer Cancer. Cell. 23, 186-199 (2013).  
149. Chen, Z. et al. miR-124 and miR-506 inhibit colorectal cancer progression by 
targeting DNMT3B and DNMT1 Oncotarget 6, 38139-38150 (2015).  
150. Hua, K. et al. Up-regulation of miR-506 inhibits cell growth and disrupt the cell cycle 
by targeting YAP in breast cancer cells Int. J. Clin. Exp. Med. 8, 12018-12027 (2015).  
151. Wen, S. Y. et al. miR-506 acts as a tumor suppressor by directly targeting the 
hedgehog pathway transcription factor Gli3 in human cervical cancer Oncogene 34, 717-
725 (2015).  
152. Deng, Q., Xie, L. & Li, H. MiR-506 suppresses cell proliferation and tumor growth by 
targeting Rho-associated protein kinase 1 in hepatocellular carcinoma Biochem. Biophys. 
Res. Commun. 467, 921-927 (2015).  
153. Li, J. et al. Downregulated miR-506 expression facilitates pancreatic cancer 
progression and chemoresistance via SPHK1/Akt/NF-ÎºB signaling. Oncogene 35, 5501 
(2016).  
154. Marchini, S. et al. Resistance to platinum-based chemotherapy is associated with 
epithelial to mesenchymal transition in epithelial ovarian cancer Eur. J. Cancer 49, 520-
530 (2013).  
155. Iwatsuki, M. et al. Epithelial-mesenchymal transition in cancer development and its 
clinical significance Cancer. Sci. 101, 293-299 (2010).  
156. Helleman, J., Smid, M., Jansen, M. P., van der Burg, M. E. & Berns, E. M. Pathway 
analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian 
cancer: the big picture Gynecol. Oncol. 117, 170-176 (2010).  
133 
 
157. Beaufort, C. M. et al. Ovarian cancer cell line panel (OCCP): clinical importance of in 
vitro morphological subtypes PLoS One 9, e103988 (2014).  
158. Pignata, S. et al. Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated 
Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The 
MITO-2 Randomized Phase III Trial. JCO 29, 3628-3635 (2011).  
159. Perrone, F. et al. Biomarker analysis of the MITO2 phase III trial of first-line 
treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC 
Oncotarget 7, 72654-72661 (2016).  
160. Zhang, Y. et al. MicroRNA-506 suppresses tumor proliferation and metastasis in 
colon cancer by directly targeting the oncogene EZH2 Oncotarget 6, 32586-32601 (2015).  
161. Sun, G., Liu, Y., Wang, K. & Xu, Z. miR-506 regulates breast cancer cell metastasis by 
targeting IQGAP1 Int. J. Oncol. 47, 1963-1970 (2015).  
162. Li, Z. et al. miR-506 Inhibits Epithelial-to-Mesenchymal Transition and Angiogenesis 
in Gastric Cancer Am. J. Pathol. 185, 2412-2420 (2015).  
163. Zhang, H., Shykind, B. & Sun, T. Approaches to manipulating microRNAs in 
neurogenesis Front. Neurosci. 6, 196 (2013).  
164. McCabe, N. et al. Deficiency in the repair of DNA damage by homologous 
recombination and sensitivity to poly(ADP-ribose) polymerase inhibition Cancer Res. 66, 
8109-8115 (2006).  
165. Wang, X. et al. Genomic instability and endoreduplication triggered by RAD17 
deletion Genes Dev. 17, 965-970 (2003).  
166. Srivas, R. et al. A Network of Conserved Synthetic Lethal Interactions for Exploration 
of Precision Cancer Therapy Mol. Cell 63, 514-525 (2016).  
167. Perren, T. J. et al. A phase 3 trial of bevacizumab in ovarian cancer N. Engl. J. Med. 
365, 2484-2496 (2011).  
168. Pujade-Lauraine, E. et al. Olaparib tablets as maintenance therapy in patients with 
platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-
Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet 
Oncology 18, 1274-1284 (2017).  
169. Rouhi, A., Mager, D. L., Humphries, R. K. & Kuchenbauer, F. MiRNAs, epigenetics, and 
cancer Mamm. Genome 19, 517-525 (2008).  
170. Lujambio, A. et al. Genetic unmasking of an epigenetically silenced microRNA in 
human cancer cells Cancer Res. 67, 1424-1429 (2007).  
134 
 
171. Lopez-Serra, P. & Esteller, M. DNA methylation-associated silencing of tumor-
suppressor microRNAs in cancer Oncogene 31, 1609-1622 (2012).  
172. Iorio, M. V. & Croce, C. M. Causes and consequences of microRNA dysregulation 
Cancer J. 18, 215-222 (2012).  
173. Arora, H., Qureshi, R. & Park, W. Y. miR-506 regulates epithelial mesenchymal 
transition in breast cancer cell lines PLoS One 8, e64273 (2013).  
174. Yin, M. et al. Selective killing of lung cancer cells by miRNA-506 molecule through 
inhibiting NF-ÎºB p65 to evoke reactive oxygen species generation and p53 activation. 
Oncogene 34, 691 (2014).  
175. Hanahan, D. & Coussens, L. M. Accessories to the crime: functions of cells recruited 
to the tumor microenvironment Cancer. Cell. 21, 309-322 (2012).  
176. Mitra, A. K. et al. Microenvironment-induced downregulation of miR-193b drives 
ovarian cancer metastasis Oncogene 34, 5923-5932 (2015).  
177. Virag, L. & Szabo, C. The therapeutic potential of poly(ADP-ribose) polymerase 
inhibitors Pharmacol. Rev. 54, 375-429 (2002).  
178. Venkitaraman, A. R. A growing network of cancer-susceptibility genes N. Engl. J. 
Med. 348, 1917-1919 (2003).  
179. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian 
carcinoma Nature 474, 609-615 (2011).  
180. Vakifahmetoglu, H., Olsson, M. & Zhivotovsky, B. Death through a tragedy: mitotic 
catastrophe Cell Death Differ. 15, 1153-1162 (2008).  
181. Reinhardt, H. C., Aslanian, A. S., Lees, J. A. & Yaffe, M. B. p53-deficient cells rely on 
ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for 
survival after DNA damage Cancer. Cell. 11, 175-189 (2007).  
182. Zabludoff, S. D. et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint 
abrogation and potentiates DNA-targeted therapies Mol. Cancer. Ther. 7, 2955-2966 
(2008).  
183. Guzi, T. J. et al. Targeting the replication checkpoint using SCH 900776, a potent and 
functionally selective CHK1 inhibitor identified via high content screening Mol. Cancer. 
Ther. 10, 591-602 (2011).  
 
